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ABSTRACT
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an endocrine disrupting environmental 
pollutant that affects bone tissue, although the mechanistic basis of such effect is far 
from clear.
In this study a proteomic approach has been adopted to investigate the disturbance of 
the osteogenic process evoked by TCDD in an in vitro osteoblast differentiation model 
of rat mesenchymal stem cells. Stem cells were isolated from bone marrow of femurs 
and tibias of rats. Progress of osteoblastic differentiation was monitored by measuring 
mRNA expression levels of differentiation markers from control and TCDD-treated cells 
after 3, 7 and 10 days of culture in presence and absence of TCDD using quantitative 
RT-PCR.
Analysis of differential protein expression in the total cell lysate of untreated and 
TCDD-treated cells was carried out over the same time points, using two-dimensional 
gel electrophoresis, computerized gel image, univariate and multivariate statistical 
analysis, in-gel digestion and tandem mass spectrometry for protein identification. 
Expression of all measured markers characteristic for various stages of osteoblastic 
differentiation (Runx2, alkaline phosphatase and osteocalcin) was dramatically reduced 
only after 10 days of TCDD exposure, indicating that TCDD significantly inhibits 
osteoblast differentiation in vitro .
Similarly, the most significant rearrangement of the proteome during osteoblast 
differentiation was observed following the 10 days of TCDD exposure, at which time 
the full progress of osteoblast differentiation should have occurred. Overall, 18 
individual proteins showed a statistically significant change in abundance as a result of 
10 days of TCDD exposure,
These proteins were mostly involved in cytoskeleton organization and biogenesis, actin 
filament-based processes, protein transport and folding. The alteration in cell
architecture and increase in cell adhesion were confirmed by confocal microscopy. The 
TCDD-induced decrease in the expression of calcium binding proteins may interfere 
with osteoblast calcium deposition, which was in fact reduced by TCDD. Evidence from 
proteomics and Western blot analysis indicated a decreased apoptotic capability in 
TCDD-treated osteoblasts.
This is the first study investigating, at the protein expression level, the effect evoked 
by TCDD during osteoblastic differentiation. Interestingly, MetaCore pathway analysis 
grouped the majority of these proteins around two principal nodes {c-fos and c-myd) 
suggesting that they may participate in the transcriptional activation of key pathways 
in TCDD-driven inhibition of osteoblast differentiation. These findings provide clues to 
the complex interplay between TCDD's action and the regulatory molecules that alter 
signal-transduction pathways regulating osteoblast differentiation and indicate new 
molecular players in the effects of TCDD on bone development.
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1.1.1. Chemical and physical characteristics
Dioxins (polychlorinated dibenzo-/?-dioxins) are ubiquitous and persistent 
environmental contaminants. The term dioxin-like is commonly used to refer to a group 
of 30 halogenated aromatic hydrocarbon that share a similar chemical structure and a 
common mechanism of toxic action. These compounds are members of three closely 
related families: 7 of the 75 congeners of polychlorinated dibenzo-/?-dioxins (CDDs), 10 
of the 135 possible congeners of chlorinated dibenzofurans (CDFs) and 13 of 209 
polychlorinated biphenyls (PCBs) congeners are thought to have dioxin-like toxicity. 
Their basic molecular structure is shown in figure 1[1].
PCormoawATto K««Hrui (pco»)
X X
Figure 1. Halogenated aromatic 
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Hydrogen atoms attached to the carbon atoms may be substituted with a chlorine 
atom. The physical/chemical properties of each congener vary according to the degree 
and position of chlorine substitution.
Dioxins are solids with high melting and boiling points. There is some variation, 
however, between the volatility of individual congeners. Dioxins are almost insoluble in
15
Introduction
water, but are quite soluble in organic solvents and fats and thus tend to 
bioaccumulate in tissue lipids and food chain.
Dioxins: environmental distribution
1.1.2.1. Emission sources
Dioxins are unintentional byproducts of thermal processes and of chemical 
formulations. The main dioxin emission sources are listed in Table 1, on the basis of 
European data [2].





MSW incineration 1,437-174 Decreasing trend3 Low/low
Sinter plants6 1,010-115 Medium/low
Residential wood 
combustion 945
Extent of contaminated wood used 
uncertain
Clinical waste incineration 816 Few plant data and statistics High/high
Wood preservation 381 From PCP-treated goods V.high/v.high
Fires 380 V.high/v.high
Non-ferrous metals 136 Cu, Al, Zn Medium/low
Road transport 111
Mainly leaded fuel; decreasing 
trend Low/low
Total 5545
a Illegal domestic burning of MSW 
b Sinter plant for recycled materials
I-TEQ international toxic equivalent, Remission factor, AR activity rate, /VSM/municipal solid waste.
Two major categories of sources can be distinguished [3\.( i)  Formation during 
incineration processes at low temperature (It has been discovered that above 800 °C 
dioxins are destroyed). This includes municipal waste combustion, scrap metal 
recycling, vehicle fuel combustion, cigarette smoking, and combustion of wood, (ii) 
Formation as by-products occurs in industrial processes, such as in the production of 
pesticides and herbicide and in the pulp and paper industry. Dioxin emissions from
16
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combustion and industrial sources can potentially be explained by three principal 
mechanisms that should not be regarded as being mutually exclusive. In the first 
mechanism (referred to as "pass through"), dioxins are present as contaminants in the 
combusted organic material; they pass through the furnace and are emitted unaltered. 
In the second mechanism (referred to as "precursor"), dioxins ultimately form from the 
thermal breakdown and molecular rearrangement of precursor ring compounds, which 
are defined as chlorinated aromatic hydrocarbons that have a structural resemblance 
to the dioxins molecules. Ringed precursors that emanate from the combustion zone 
are a result of the incomplete oxidation of the constituents of the feed {i.e., products 
of incomplete combustion. The third mechanism (referred to as "de /701/0 synthesis") is 
similar to the precursor mechanism. De novo synthesis describes a pathway of dioxins 
formation from heterogeneous reactions on fly ash (particulate matter) involving 
carbon, oxygen, hydrogen, chlorine, and a transition metal catalyst. With these 
reactions, intermediate compounds that have an aromatic ring structure are formed. 
Moreover, mobilization of dioxins from secondary sources, such as waste dumps and 
the application of sewage sludge for fertilization, may occur.
1.1.2.2. Human exposure sources
Dioxins are highly persistent in the environment and are ubiquitously present as 
mixtures in soil, sediments and air. Due to their lipophilicity, dioxins tend to accumulate 
in the fat, having a high biological half-life and consequently they bio-magnify in the 
food chain. Over 90 % of human background exposure to dioxins occurs through the 
diet, from animal origin [4]. Moreover occupational {e.g. as a result of production and 
use of chlorophenols and chlorophenoxy herbicides) and accidental (Seveso 1976 e.g.) 




Dioxin causes a wide array of adverse health effects in both animals and humans. The 
wide range of health effects of dioxins are species- and sex-dependent. The type of 
exposure (acute vs. chronic) and the amount of exposure are also important 
determinants of the ultimate toxic effects dioxin exposure [6].
2,3,7,8-tetrachloro-p-dioxin (TCDD) is the most toxic dioxin congener and is the 
prototypical representative of this class of persistent environmental contaminants [7]. 
Since dioxins differ in their toxic potential, the toxic equivalence factor (TEF) of each 
dioxin congener is evaluated in relation to the most toxic one (TCDD), so the toxicity of 
a mixture can be expressed in terms of its Toxic Equivalents (TEQ), which is the 
amount of TCDD it would take to equal the combined toxic effect of all the dioxins 
found in that mixture [8].
1.1.3.1. Toxicological effects on humans and risk assessment
Short-term exposure of humans to high levels of dioxins occurred during accidental 
exposure may result in skin lesions, such as chloracne and patchy darkening of the 
skin, and altered liver function [9]. Long-term exposure is linked to impairment of the 
immune system, of nervous system development, of the endocrine system and 
reproductive functions [10]. TCDD is also considered to be a "known human 
carcinogen" [2, 8,11].
Although human intake levels of TCDD have decreased notably over the past two 
decades, a significant baseline exposure to dioxin appears to be inevitable and there 
are some subgroups in the population that are exposed to higher intakes of dioxins 
[12,13].
In the last few years the risk assessment for dioxins and dioxin-like (DL) compounds 
has been revised. The Scientific Committee on Food of the European Commission (EC
18
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SCF) updated its opinion on the risk assessment of PCDDs, PCDFs and DL-PCBs and 
adopted a tolerable weekly intake (TWI) of 14 pg TEQ(i998) pc d d s / fs+ d l -pcbs kg-bw-1 [14], 
whereas the joint FAO/WHO [15]. Expert Committee on Food Additives (JECFA) 
established a Provisional Tolerable Monthly Intake (PTMI) of 70 pg WHO-TEQ(i998)
PCDDs/Fs +  DL-PCBs k g - b W - 1 .
1.1.3.2. Toxicological effects on animal models
Dioxin causes a wide range of toxic effects on laboratory animals [6]. These include: 
Wasting Syndrome
Dioxins are some of the most anorexogenic compounds known. Wasting is the main 
cause of death in laboratory animals exposed to high doses of dioxin-like compounds. 
This wasting syndrome mainly results from hypophagia, but the exact mechanisms of 
wasting are still unknown [16, 17]. Significant studies have suggested a causative 
relationship between increased levels of plasma free tryptophan and increased brain 
serotonin synthesis, thereby suppressing food intake has been proposed.
Interference with vitamin A system
Decreased hepatic vitamin A stores occur at exposure levels as low as 14 ng 
TCDD/kg/day in rats [18, 19] levels at which very few other measurable effects of 
dioxin exposure can be observed. Other effects on the vitamin A system include altered 




Immunosuppression is described as one of the most sensitive effects of organochlorine 
exposure. Juvenile rats fed a few nanograms of TCDD /kg body weight/day for 25 days 
displayed a significant impaired immune system, including reduced thymic cellularity 
and splenocyte functionality and lower populations of circulating mature T-lymphocytes 
[21].
Cancer
Examples of the cell-cycle-toxic/tumorogenic effect of TCDD include the ability to 
decrease levels of cellular growth factors such as TGFbeta [22], to create chromosomal 
instability through indirect suppression of the mitotic checkpoint protein MAD2 [23] 
and to promote direct protein-protein interactions between the AHR and 
retinoblastoma (Rb) protein that controls cell cycle progression through G1 phase [24]. 
Interestingly recent findings in AHR over-expressing mice suggest that chronic AHR 
activation may lead to stomach tumors [25]. Thus, total absence of AHR activation as 
well as chronic inappropriate activation, may both promote carcinogenesis.
Diabetes
The role of dioxin in type 2 diabetes has been widely studied in Vietnam war veterans 
exposed to dioxins via the AGENT Orange. Veterans with high blood levels of TCDD 
had greater prevalence of diabetes and were more likely to be hyperinsulinemic [26]. 
The molecular mechanism(s) for TCDD interference with insulin action is not well 
defined, but involves the PPAR/RXR signalling pathway [27].
20
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Disturbance in the CNS
TCDD has well-known adverse effects on the brain and neuronal functions. Specific 
targets for adverse effects of dioxins on the CNS include dopamine synthesis and 
signaling, serotonin metabolism, cholinergic nicotine receptor levels and tryptophan 
levels [28, 29].
Adverse effects on male and female reproduction
TCDD has adverse effects on male reproduction system, resulting in decreased weights 
of the testis, epidydimis, seminal vesicle as well as in decreased sperm production 
[30]. Anti-androgenic effects of dioxins identified at molecular level include altered 
levels, metabolism, and signalling of testosterone as well as estrogen [31]. Recently, a 
direct physical interaction between liganded AHR and estrogen receptor ER (both alpha 
and beta isoforms) was shown, which enhanced ER signalling [32].TCDD has anti­
estrogenic effects in females. Dioxin inhibits the action of estrogen in females of 
several species and disrupts normal estrous cycling. Other indicators of its 
antiestrogenic actions are uterine atrophy and decreased number of corpora lutea. 
Many studies have demonstrated the existence of inhibitory AHR-estrogen receptor 
(ER) cross-talk in rodent uteri and mammary glands.
1.1.4. Mechanisms o f action
The molecular mechanisms underlying the multifaceted toxicity of TCDD are still largely 
unknown, although it has been shown that many of its biochemical and toxic effects 
are mediated by the aryl hydrocarbon receptor AHR (figure 2) [33].
21
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Figure 2. Aryl Hydrocarbon receptor molecular mechanism.
1.1.4.1. Mechanism o f action via AHR
The aryl hydrocarbon receptor (AHR) is a member of the basic helix-loop-helix (bHLH)- 
Per-ARNT-Sim (PAS) family of transcriptional regulators and is highly conserved among 
the mammalian species. Unliganded inactive AHR is located in the cytoplasm associated 
with heat shock protein 90 (HSP90) and a 38 kDa, immunophilin-related protein (XAP2) 
and some other auxiliary chaperones [34]. Ligand binding to the AHR is presumed to 
produce conformational changes in the AHR protein, which results in the exposure of 
an AHR nuclear localization signal and the translocation of the whole complex into the 
nucleus. Within the nucleus, the AHR-ligand complex dissociates from associated 
proteins and dimerizes with ARNT to reconstitute an active transcription factor, which 
binds with high affinity to a specific DNA sequence, known as aryl hydrocarbon 
response element I (AHRE-I) or xenobiotic-responsive element (XRE), or dioxin- 
responsive element (DRE). This sequence is located in regulatory regions of aryl 
hydrocarbon-responsive genes (table 2, AHRE-I sequence). Binding to the AHRE-I 
activates the transcription of a battery of target genes, the most known of which is the 
cytochrome P450 1A1 (CYP1A1) [35, 36].
22
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The aryl hydrocarbon receptor repressor (AHRR) is a negative regulator of AHR, which 
acts by competing with AHR for dimerization of ARNT and for binding to the AHRE-I 
sequence. In addition, AHRR is inducible by AHR ligands and thus regulates AHR 
function by a negative feedback mechanism affecting the expression of genes induced 
by dioxins [37, 38].
Recently, it has been proposed that the AHR-ARNT heterodimer may bind to another 
response element called AHRE-II (table 2, AHRE -II sequence) while associated with 
an unidentified factor [39]. Binding of this complex appears to lead to the activation of 
a novel, functionally coherent battery of genes [40, 41].
Table 2. Response element site sequences.






Exposure to TCDD and subsequent recruitment of ARNT through AHR may inhibit 
further signal transduction pathways depending on ARNT [42]. Thus, through its ability 
to interact with multiple signal transduction pathways and to induce or inhibit a variety 
of gene products, AHR agonists are capable of inducing a wide spectrum of biological 
effects at a number of different life stages and in a variety of species.
TCDD-induced changes in gene expression may also occur indirectly as a consequence 
of an AHR/ARNT-dependent induction of oxidative stress and the transcriptional 
activation of a further set of genes via a different enhancer, the so-called antioxidant 
response element (ARE) [43].
One of the major causes of dioxin's toxicity is dioxin-evoked stress responses. It has 
been noted that dioxin causes typical cellular stress symptoms in affected cells. In
23
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addition to oxidative stress, there are many documented signs of other types of cellular 
stresses induced by dioxin in various cell types.
It is well acknowledged that many forms of well-studied cell stressors utilize defined 
major pathways sometimes designated as stress-activated kinase pathways. Each 
stress-activated kinase pathway may be distinguished from others by a unique MAPK 
(here used as a generic designation) that not only mediates stress signal transduction, 
but also acts as the anchor component carrying the final message to the nucleus of the 
affected cell [44] (figure 3).
It is been suggested that one of the most active pathways in dioxin signalling is the 
extracellular signal-regulated protein kinases (ERK) pathway, whose dioxin-induced 
activation is mediated by the stress-induced growth factor TGFalpha, an autocrine 
factor produced and secreted by many types of cells into the extracellular matrix [45].
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Figure 3. Schematic representation of major stress-activated kinase pathways. The pathway 




1.1.4.2. Other mechanisms o f action
Although the evidence supports the hypothesis that most of the effects of TCDD are 
mediated through the AHR, there are several effects of TCDD that have been 
attributed to an AHR-independent mechanism.
For example TCDD has been reported to activate MAP kinases, such as Jun N-terminal 
kinase (JNK) and extracellular signal-regulated kinase (ERK), independently of AHR 
[46]. However, it remains to be clearly determined whether there is a cross-talk with 
AHR through the common regulator proteins shared by these different pathways.
Thus the mechanisms by which TCDD may interfere with signalling pathways appear to 
be extremely complex, and the elucidation of the resulting alterations in gene 
expression and their importance for the various aspects of TCDD toxicity clearly 
remains a continuing challenge.
1.1.5. TCDD as endocrine disruptor
It has been widely reported that endocrine disruptors can act at multiple sites via 
multiple mechanisms of action. Receptor-mediated mechanisms have received the 
most attention, but other mechanisms {e.g., hormone synthesis, transport, and 
metabolism) have been shown to be equally important [31, 47].
Research on endocrine disruption effects and mechanisms is rather complex, since 
exposure to the same level of an endocrine signal during different life ages may 
produce different effects.
The prenatal and perinatal periods are particular sensitive to dioxin exposure, and 
indeed, higher exposure doses are required to produce similar effects in adult animals.
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Usually exposure in adulthood may be compensated by normal homeostatic 
mechanisms and may therefore not result in any significant or detectable effects. 
Moreover, because of cross talk between different components of the endocrine 
systems, effects may occur unpredictably in endocrine target tissues other than the 
system predicted to be affected [48].
Thus, for most reported associations between endocrine disruptors exposure and 
different biologic outcomes, the mechanism(s) of action are poorly understood and 
involve several different pathways.
Exposure to dioxins has the potential to disrupt multiple endocrine pathways and 
induce toxic responses. Experimental animal data have shown adverse effects in 
testicular function, including reduced sperm counts and motility [49-51].
Reproductive organs and the endocrine system are sensitive to TCDD during 
development and sexual maturation [52-54]. Compared to placental transfer, exposure 
via lactation plays a major role in offspring receiving maternal dioxins [55]. In utero 
and lactational TCDD exposure in rats has been associated with reduced ovarian weigh 
and decreased estradiol [56]. Similar outcomes have been reported in primates, 
including decreases in estradiol and progesterone [57, 58].
Some evidences suggest that TCDD could alter human ovarian function, including 
steroidogenesis and ovulation [59, 60].
No definitive data are available for humans, but recently Mocarelli et al [10] observed 
that exposure to TCDD from infancy through puberty produces a reduction in serum 
17beta-estradiol and a permanent effect of semen quality in human males as a result 
of the disruptive action of low concentrations of TCDD on the endocrine system.
It has been proposed that endocrine disrupters also affect non-reproductive tissues 
such as bone. Therefore, the next section considers bone biology and its regulation.
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1.2. General aspects on bone
1.2.1. Bone tissue macroscopic organization: anatomy and physiology
The skeletal system consists of cartilage and bone, a highly specialized connective 
tissue characterized from an organic mineralized extracellular matrix. Although 
macroscopically the skeleton seems to be a static organ, bone is an extremely dynamic 
tissue at the microscopic level.
In fact bone undergoes constant remodelling, which renews the tissue and maintains 
the bone mass constant [61].
Bone serves three main functions: mechanical, protective and metabolic. In fact the 
skeleton is the site of muscle attachment for locomotion and provides internal support 
to the body in all higher vertebrates protecting vital organs and bone marrow.
In addition to its supportive function, it has several metabolic functions and plays an 
essential role in maintaining blood calcium and phosphate levels.
Morphologically, bone tissue is divided into cortical/compact bone, which forms about 
80% of the mature skeleton, and cancellous/trabecular bone.
Both of them have the same matrix composition, but they differ structurally and 
functionally.
Cortical bone has higher density and less porosity compared to cancellous bone so the 
cortical bone fulfills mainly (but not exclusively) a mechanical and protective function 
and the trabecular bone a metabolic function.
Mature cortical bone consists of densely packed sheets of collagen lamella, concentric, 
parallel and interstitial, organized in a functional unit named an osteon or the 
Haversian System; whereas in cancellous bone the matrix is a meshwork of bars and 
spicules of bone lamella, thus it is more loosely organized.
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Anatomically, bones are classified into three primary groups based on their general 
shape: short, flat, or long bones. Short bones (carpals and vertebral body, e.g.) are 
approximately the same in measurement in all directions and possess a trapezoidal, 
cuboidal, cuneiform, or irregular shape. Flat bones have one dimension that differs in 
length from the other two. The bones of the skull, scapula, mandible, and ilium are 
examples of flat bones. Long bones, such as tibia, femur, and humerus, consist of 
three anatomical divisions: the epiphyses, the metaphyses, and the diaphysis (figure 
4). The diaphysis, or shaft of the bone, is a hollow cylinder in shape, surrounded by a 
layer of cortical bone. Diaphysis encloses the medullary cavity where the hematopoietic 
bone marrow is housed. The epiphysis is the ends of the bone and consists of a thin 
cortical layer of bone surrounding trabecular bone. The spaces enclosed by these thin 
trabeculae are also filled with hematopoietic bone marrow and are in continuity with 
the medullary cavity of the diaphysis. The metaphysis is the region of the bone 
between the epiphysis and diaphysis, containing both trabecular and cortical bone.

















Figure 4. Schematic view of a long bone and its organization,
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A plate of cartilage separates the epiphysis from the metaphysis and is known as the 
epiphyseal growth plate; this plate is the site at which elongation of long bones can 
occur. There are consequently two bone surfaces at which the bone is in contact with 
the soft tissues; both of them are lined with osteogenic cells organized in layers. The 
outer surface of the bone is known as the periosteum and the inner surface is known 
as the endosteum. There are two types of processes involved in bone development: 
intramembranous ossification (flat bones and bone formation occurring during bone 
remodelling) and endochondral ossification (long bones), characterized by the 
presence of a cartilaginous phase.
1.2.2. Bone cells and bone m atrix composition
Four different types of cells reside in bone: 1) bone-forming osteoblasts, 2) osteocytes 
that sense mechanical strains and are trapped in bone matrix, 3) lining cells covering 
the bone tissue, 4) bone-resorbing osteoclasts.
1.2.2.1. Osteoblasts
The osteoblast is the cell responsible for the production of the matrix constituents. It 
originates from local mesenchymal stem cells under the influence of several growth 
factors that will be described more in detail in paragraph 1.3.
Morphologically, active osteoblasts are cuboidal cells with a large nucleus, usually 
found in a single layer adherent to periosteal or endosteal surfaces of bone.
Since the main function of osteoblasts is the secretion of a complex mixture of bone 
matrix proteins (known as osteoid) active osteoblasts have a prominent Golgi complex 
and abundant rough endoplasmic reticulum. As polarised cells, they secrete osteoid
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unidirectionally towards the bone surface on which they lie. Osteoblasts form tight 
junctions with adjacent osteoblasts, and possess specialized regions of their plasma 
membrane modified for vesicular trafficking and secretion. Osteoblasts are normally 
separated from the mineralized bone matrix by a thin layer of universalized matrix, the 
osteoid seam [62].
Osteoblasts also assist in the homeostasis of calcium by possessing receptors for the 
two primary calcium and bone regulating hormones, parathyroidhormone and 1,25- 
dihydroxyvitamin D (details in section 1.2.4).
Active osteoblasts may follow one of three courses once bone has been formed: 1) 
enclose themselves in bone, forming osteocytes, 2) remain on the bone surface, 
forming bone-lining cells, or 3) disappear from the site of bone formation by 
undergoing apoptosis.
1.2.2.2. Osteocytes
Osteocytes, the most abundant cells in bone, permeate the mineralized bone matrix 
occupying individual lacunae. In fact they derive from osteoblasts which become 
enclosed within the bone matrix during bone formation. Osteocytes have a typical 
morphology with long thin cytoplasmic processes, which form, in bone matrix, a fine 
network of connections (canaculi) with other osteocytes and with the osteoblasts and 
bone lining cells located at the surface of the bone [63]. They are believed to maintain 
the bone by responding to the mechanical stimuli and sensing bone damage.
1.2.2.3. Bone lining cells
Bone lining cells are mainly derived from osteoblasts that have become inactive. They 
are flattened, elongated cells covering quiescent the majority of the adult bone surface 
and thereby separate the bone surface from the bone marrow.
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Bone lining cells are characterized from cytoplasmic extensions penetrating the bone 
matrix in order to get in contact with the extensions of osteocytes.
Bone lining cells are believed to be central in the maintenance of blood calcium and 
phosphate levels, and may have a role in attracting and stimulating osteoclasts to 
resorb bone.
1.2.2.4. Osteoclasts
Osteoclasts, responsible for the resorption of bone matrix during bone remodelling, are 
multinucleated giant cells arising from the fusion of mononuclear precursors, 
originating from hematopoietic stem cells in marrow. They contain from 1 to more than 
50 nuclei and range in diameter from 20 to over 100 pm.
In order to attend their bone resorbing role, they locate on bone surfaces tightly 
associated with the calcified matrix. Osteoclasts are polarised cells, having a ruffled 
border region of the cell membrane that is surrounded by an organelle-free region, or 
'clear zone1, which adheres to the bone surface via integrins, which are specialised cell 
surface receptors [63-65]. Osteoclastic bone resorption initially involves mineral 
dissolution, followed by degradation of the organic phase. These processes take place 
beneath the ruffled border and depend on lysosomal enzyme secretion and an acid 
microenvironment. Generally osteoclasts undergo apoptosis after a cycle of resorption, 
a process favored by estrogens. Bone resorption is strictly correlated with the 




1.2.2.5. Bone matrix composition and organization
Bone matrix makes up more than 90% of the volume of the bone tissue. The 
extracellular matrix contains 35% organic, 65% inorganic components and the water 
component is 10%.
Approximately 90% of the organic matrix consists mainly of collagen type I, which is 
organized in fibers preferentially oriented in a specific direction. The non-collagenous 
proteins are composed of non-collagenous glycoproteins and bone specific 
proteoglycans, including osteocalcin, osteonectin, bone phosphoproteins, bone 
sialoproteins and small proteoglycans. There are also a large number of proteins that 
are absorbed from the circulation. The non collagenous proteins have different 
functions in the regulation of bone mineralization, e.g. they mediate cell-to-matrix 
binding and act as growth factors.
The inorganic phase of bone matrix performs two essential functions: it is an ion 
reservoir and gives the bone tissue its stiffness and strength. Approximately 99% of 
body calcium, 85% of the phosphorous and 40-60% of total body sodium and 
magnesium are associated in mineral crystals in bone tissue. The physiologic 
concentrations of these ions in the extracellular fluid are thereby sustained. By forming 
hydroxyapatite-crystals (Caio[P04][OH2]) of calcium and phosphate the bone tissue is 
provided with stiffness and strength. Crystals tend to be oriented in the same direction 
as the collagen fibers. The preferential orientation of the collagen fibers alternates in 
adult bone from layer to layer, giving to this bone a typical lamellar structure.
The lamellae can be parallel to each other if deposited along a flat surface (trabecular 
bone and periosteum), or concentric if deposited on a surface surrounding a channel, 
the Haversian canal) containing blood and, sometimes, nerves. The Haversian system 
or osteon consists of such central canal, surrounding osteocytes and canaculi. The 
Haversian canals have an impressive network with transversely oriented canals,
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Volkmans canals. The network of canals connects the periostal and endosteal surface 
and the bone marrow enabling regulation of cell and bone metabolism.
However, when bone is being formed very rapidly (e.g. during development and 
fracture healing and some metabolic bone diseases), there is no preferential 
organization of the collagen fibers. They are not as tightly packed and found in 
somewhat randomly oriented bundles; this type of bone is called woven bone and is 
generally replaced in a second time by cortical tissue.
1.2.3. Bone remodelling
To carry out its metabolic function and the maintenance of the bone mass, bone is 
continuously resorbed by osteoclasts and subsequently rebuilt by osteoblasts that 
restore bone by synthesizing new bone matrix. This process is called bone remodelling, 
whose main function is to renew bone tissue to retain bone strength during adulthood 
[66].
Remodelling is most vigorous during the years of active growth, when deposition 
predominates over resorption.
Bone development and later remodelling are regulated by complex control systems 
that involve several types of intercellular signalling, between the osteoprogenitor cells 
and mature osteoblasts, osteocytes and osteoclasts.
Bone remodelling takes place in bone remodelling units comprising osteoblasts, 
osteoclasts and their precursors, in which resorption and formation are coupled [67]. 
Osteocytes are also marginally involved in the process by soluble factors or directly 
through cell to cell contacts. The bone remodelling cycle involves a complex series of 
sequential steps that are highly regulated. The main phases are 1) osteoclastic
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resorption, 2) reversal phase, 3) preosteoblastic migration and differentiation into 
osteoblasts 4) osteoblastic matrix formation and 5) mineralization.
Bone formation and bone resorption do not, however, occur along the bone surface at 
random; they are either part of the process of bone development and growth or part 
of the turnover mechanism by which old bone is replaced by new bone. In the normal 
adult skeleton {i.e., after the period of development and growth), bone formation 
occurs for the most part only where bone resorption has previously occurred. During 
the intermediate phase between resorption and formation (the reversal phase), some 
macrophage-like, uncharacterized mononuclear cells are observed at the site of the 
remodelling, and a cement line is formed, which marks the limit of resorption and acts 
to cement together the old and the new bone.
During skeletal development and bone remodelling throughout life, the cells from the 
osteoblast lineage synthesize and secrete molecules that in turn initiate and control 
osteoclast differentiation. Osteoblasts secrete two proteins, the receptor activator of 
nuclear factor-kB ligand (RANKL) and osteoprotegerin (OPG), which are responsible for 
the communication between osteoclasts and their precursors (figure 5) [68, 69].
These two molecules have antagonistic effects on bone mass; while RANKL induces 
bone resorption, OPG blocks it. The receptor RANK is in fact required in conjunction 
with macrophage colony stimulating factor (MSCF) for osteoclast differentiation.
OPG inhibits spontaneous or induced bone resorption. OPG acts as a decoy receptor 
that binds to RANKL and prevents it from interacting with its receptor [70].
RANKL and OPG, both of which are produced by osteoblasts at different stages of 
maturity, account for some of the signals in osteoblast-osteoclast communication.
The signal(s) that couples resorption and formation remains elusive, although several 
of the anabolic ligands, such as bone morphogenic proteins (BMPs) and transforming 
growth factor (3 (TGFB) are stored in bone matrix as bone is formed and are released
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during bone resorption and can thus act on osteoblasts and precursors in the vicinity. 
BMPs could also enhance osteoclast differentiation from progenitors.
Besides that osteoclast activity is coupled to osteoblast activity, the activity of 
osteoblasts is also influenced by the activity of osteoclasts. During osteoclastic bone 
resorption multiple factors are released from the extracellular matrix, including insulin- 
growth factor I (IGF-I) and TGFp, which control the differentiation and activity of 
osteoblasts after their release {paragraph 1.3).
Although bone resorption and formation are coupled, this process is not always in 
balance.
During growth, the balance favors bone formation to reach peak bone mass. After 
adults reach their peak bone mass there is evidence of a reduction of bone formation, 
which eventually results in bone loss and structural bone damage during ageing. The 
reduced bone mass, for instance, in osteoporosis results from an imbalance between 
bone resorption and formation, with the rate of resorption exceeding that of formation. 
In case of hormonal imbalance the coupling between osteoblasts and osteoclasts can 
also be out of equilibrium (details in paragraph 1.2.4).
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Many cytokines are also important factors for the normal bone remodelling sequence. 
IL-1 is released by osteoblasts and it is a potent stimulator of osteoclasts. It works at 
all phases in the formation and activation of osteoclasts. Its effects are mediated 
through RANKL [71]. IL-6 is a pleiotropic cytokine expressed and secreted by normal 
bone in response to osteotropic hormones such as parathyroid hormone and 
dihydroxyvitamin D {paragraph 1.2.4). It has been implicated in the bone loss- 
associated skeletal metastases and with estrogen withdrawal in mouse models [72]. 
IL-15 and IL-17, both produced by T-cells, stimulate osteoclastogenesis and bone 
resorption [73, 74]. On the contrary, IL-18, a pro-inflammatory cytokine homologous 
to IL-1, inhibits osteoclast formation [75],
There are a number of other factors whose role in physiological and pathological bone 
remodelling is still to be clearly delineated. These include for example:
- Retinoids. Vitamin A excess eventually leads to increased bone resorption in vivo and 
hypercalcemia [76].
- TGF-aipha\ TGF-alpha is a powerful stimulator of osteoclastic bone resorption. It 
stimulates the proliferation of osteoclast progenitors and probably acts on nonmature 
multinucleated cells. Its effects on bone cells are mediated through the epidermal 
growth factor (EGF) receptor [77].
1.2.4. Bone remodelling and systemic hormones
The fact that bone remodelling occurs simultaneously in multiple skeletal locations is 
generally viewed as evidence that it is controlled locally, through autocrine and /or 
paracrine mechanisms [62]. This observation is also consistent with the possibility that 
bone remodelling is under endocrine control. Accordingly, several hormones are
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already known to control bone remodelling. For instance, sexual steroid hormones such 
as estradiol are involved in the control of bone remodelling by affecting osteoclast 
differentiation and thereby bone resorption. As a result, the decline in levels of sexual 
steroid hormones at menopause is a predisposing factor for osteoporosis [62]. Like 
estrogens, androgens influence bone development with dramatic clinical 
manifestations. Decreased androgen levels have been linked to lower bone density in 
men, and there is a strong correlation between hypogonadism in elderly men and hip 
fracture and spinal osteoporosis [78].
Parathyroid hormone (PTH) has complex and only partially understood actions on 
bone. Paradoxically PTH has a catabolic effect (increase bone resorption) and an 
anabolic effect on bone (increase bone formation) depending on the dose and on the 
mode of administration (continuous versus intermittent) [79].
Another systemic hormone such as dihydroxyvitamin D [l,25(OH)2D3] has a multiple 
and complex effects on bone. Like PTH, it stimulates osteoclastic bone resorption by 
stimulating differentiation of osteoclast progenitors but also activates mature 
osteoclasts.
On the contrary, calcitonin is potent inhibitor of bone resorption, but its effects are 
only transient.
Other systemic hormones are important in regulating skeletal growth. The growth 
hormone is "anabolic", which means it stimulates bone formation, glucocorticoids are 
necessary for bone cell differentiation during development and thyroid hormones can 





The osteoblastic lineage cells that mediate bone formation are comprising the following 
phenotypes: mesenchymal stem cells that give rise to osteoprogenitor cells as well as 
the cells of other lineages; osteoprogenitor cells that contribute to maintaining the 
osteoblast population and bone mass; pre-osteoblasts, cells that started the 
differentiation process but not yet synthesising bone matrix; osteoblasts that 
synthesise the bone matrix on bone forming surfaces [80]; osteocytes, organised 
through the mineralized bone matrix that support bone structure, and lining cells that 
protect the bone surface.
1.3.1. Mesenchymal stem cells
Postnatal bone marrow stroma contains cells that have both significant proliferative 
capacity and the capacity to form osteoblasts, chondroblasts, adipocytes and myoblatst 
under appropriate conditions [81-83]. These are mesenchymal-derived stem cells, 
commonly referred to as mesenchymal stem cells (MSC) or stromal cells and are 
distinguished from the hematopoietic stem cell lineage present in bone marrow. 
Commitment of MSCs to tissue-specific cell types is orchestrated by transcription factor 
regulators that serve as "master switches". As shown in the figure 6, two transcription 
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Figure 6. Stem cell commitment to mesenchymal phenotypes. A schematic of stem cell commitment 
through either (A) a single step process or (B) a multistep hierarchical process with increasing lineage 
restriction to various end-stage mesenchymal cell types. Some of the known transcription factors playing 
key regulatory roles in the mesenchymal lineages are indicated. Also depicted is apparent plasticity 
between osteoblasts and adipocytes. [86].
1.3.2. Osteoblast differentiation process
The progression of osteoblast maturation requires a sequential activation and 
suppression of genes that encode the phenotypic and functional proteins of the 
osteoblast populations. Signalling proteins, transcriptions factors and regulatory 
proteins support the temporal expression of genes that characterize stages of 
osteoblast differentiation and bone formation.
As shown in figure 7, the process of osteoblast differentiation can be divided in three 
main subsequent steps: (i) proliferation, (ii) matrix synthesis and maturation and (iii) 
mineralization. Each stage is characterized by the expression of distinctive osteoblast 
markers. Most frequently used markers of osteoblastogenesis are: transcription factor 
RUNX2 (called also cbfal) which is expressed in a period of active proliferation,
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alkaline phosphatase (ALP) in matrix maturation, and osteocalcin (OCN) in the onset of 
mineralization [87, 88].
The ordered temporal expressions of these genes were used as specific markers for 
osteoblastic differentiation in this study.
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Figure 7. Growth and differentiation of osteoblasts. Schematic illustration of (A) frequently used markers 
of (B) osteoblast maturation stages. (C) The bone morphogenetic proteins (BMP2/4/7) are required for 
lineage direction. At each stage of maturation, cells are responsive to steroid and polypeptide hormones 
that promote their further differentiation, as well as mediating their functional activities (e.g., PGE2, IGF- 
1). Selected examples of regulatory factors are shown [86].
1.3.2.1. Transcription factors controlling osteobiastogenesis
The role of the most important transcription factors governing osteoblasts 
differentiation is summarized here.
Runx2
Runt-related transcription factor 2 (Runx2, called also cbfal) is the earliest marker of 
osteoblast lineage cells and it is necessary, but not sufficient, for a progenitor cell to 
differentiate along the osteoblast lineage.
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Runx2 operates in bone lineage cells mainly by binding to the Runx consensus 
sequence 5'- PYGPYGGT-31, named also osteoblast specific element (OSE2).
The Runx regulatory element can be found in the promoter of all major osteoblast 
genes controlling their expression, including type I collagen alpha 1 chain, osteopontin, 
vascular endothelial growth factor (VEGF), RANKL, sclerostin, bone sialoprotein and 
osteocalcin, resulting in the establishment of an osteoblast phenotype. Additionally, 
Runx2 can be phosphorylated and activated by the mitogen-activated protein kinase 
(MAPK) pathway by binding of type I collagen to alpha2betal-integrins on the 
osteoblast surface [89].
In addition to control osteoblast differentiation, Runx2 was found to negatively control 
osteoblast proliferation by acting on the cell cycle [90]. Moreover Runx2 can modulate 
the expression of kinases such as p85 PI3K that controls osteoblast differentiation and 
survival [91]. Recent studies indicate that Runx2 interacts with several regulatory 
proteins within the nuclear architecture, resulting in activation or repression of genes 
which control the program of osteoblast proliferation and differentiation [92], This 
indicates that Runx2 can control osteoblastogenesis through multiple mechanisms.
Osterix
Osterix (Osx), also known as SP7 transcription factor, is zinc finger transcription factor 
essential for the formation of preosteoblasts from multipotent progenitors. In fact Osx- 
deficient mice show absence of osteoblasts and defective bone formation [93]. 
However, Runx2 is expressed in Osx-deficient mice, indicating that Osx acts
downstream of Runx2. Osx transcription is positively governed by Runx2 and acts by
!
directing pre-osteoblasts to immature osteoblasts; Osx in turn, impairs osteoblast 
differentiation. Although little is known on the mechanisms of action of Osx, this
protein was found to form a complex with the nuclear factor of activated T cells
I ■ •
(NFAT), resulting in activation of type I collagen alpha promoter activity [94].
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Accordingly, constitutive activation of NFAT activates the Wnt signalling pathway, bone 
formation and bone mass. Osterix is also a suppressor of VEGF expression following 
endothelin-1 exposure; therefore, it might be a crucial mediator of osteoblast function 
within the context of bone remodelling.
(3-Catenin
Genetic studies have revealed that canonical Wnt signalling is an important pathway 
controlling bone formation and bone mass [95, 96]. Inactivation of (3-Catenin blunts 
osteoblast differentiation from mesenchymal progenitors, indicating that (3-Catenin 
plays an essential role in osteoblast differentiation in vivo [97]. One of the targets of 
Wnt signalling is Runx2 as (3-Catenin/TCFl promotes Runx2 expression and activity 
[98]. One Wnt protein, WntlOb, was found to induce the expression of Runx2, Osx and 
Dlx5 and to reduce the expression of adipogenic transcription factors C/EBPand PPARy 
in mice, indicating that Wnt signalling controls osteoblastogenesis and bone mass by 
modulating several transcription factors [99].
ATM
ATF4 or CREB2 (cAMP response elements binding protein2) is another important 
transcription factor controlling osteoblasts. ATF4 interacts with Runx2 to regulate the 
transcriptional activity of osteocalcin [100]. Additionally, ATF4 can be phosphorylated 
by the kinase Rsk2 and thereby controls amino acid transportation in osteoblasts, an 
important step in bone formation. ATF4 is a ubiquitous protein expressed in many cells 
but it is degraded in osteoblasts after its ubiquitination. ATF4 is therefore a 




API, a transcription factor composed of heterodimeric proteins of the Fos and Jun 
families (c-Jun, JunB et JunD; c-Fos, FosB, Fra-1, Fra-2) is an important regulator of 
bone formation, as demonstrated by genetic manipulations in mice [102]. c-Fos is the 
first member of the API family of transcription factors that was recognised to regulate 
osteoblast proliferation and gene expression[103]. More recent studies showed that 
other members control osteoblast differentiation. In  vivo, overexpression of Fra-1 or 
AFosB (a splice variant of FosB) promotes osteoblast differentiation and thereby bone 
formation and bone mass resulting from increased number of osteoblasts [104]. On 
the contrary, down-regulation of Fral or JunB results in reduced bone formation and 
bone mass in mice [105]. Besides direct effects on osteoblast gene transactivation, 
some API members can act with other transcription factors. For example, Jun proteins 
can heterodimerize with ATF4 to control gene expression [106]. Thus, the API family 
of transcription factors can control osteoblast differentiation by acting at multiple 
levels.
PPARy2
In addition to Runx2, other transcription factors play a role in lineage determination. 
Proliferation-activated receptor y2 (PPARy2) is known to be involved in the 
differentiation of mesenchymal cells into osteoblasts. Consistently, increased 
expression of PPARy2 induces adipocyte differentiation and reduces osteoblast 
differentiation in mesenchymal cells [107] whereas, as expected, forced expression of 
Runx2 in adipocytes results in osteoblast differentiation [108]. In addition to inducing 
adipocyte gene expression, PPARy2 can bind Runx2 and inhibit its transcriptional 
activity. Consistent with these in vitro data, PPARy2 removal in mice promotes 
osteoblast differentiation resulting in increased bone mass [109]. The role of these 
transcription factors in the inverse relationship between osteoblastogenesis and
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adipogenesis in the bone marrow stroma in osteopenic disorders and aging remains, 
however, to be determined.
I.3.2.2. Regulation o f transcription factors in osteoblasts
Numerous secreted factors of paracrine, autocrine, and endocrine origin influence 
osteoblast development and maturation.
Figure 8 summarizes the effects of many local and external factors which exert 































BMP2: Bene morphogenetic protein 2 
C/®Pa: Ccaat-enhancer-binding proteins alpha 
E2: estradiol
FGF2: Basic fibroblast growth factor
FGFR2 : Fbnoblast growth factor receptor 2
GC: group-specific component, vitamin D binding protein
GH; growth hormone
IGF1: Insuiin-lke growth factor 1
Ihh:Indian hedgehog homobg
L F -l: lymphoid enhancer factor 1
Osx: Osterix
PGE2: prostagiandh E2
PPARy: Peroxisome proliferator-activated receptor gamma
PTH: Parathyroid hormone
RUNX2: Runt-related transaction factor 2
TGF£: Transfermirg growth factor beta
Vit D: vitamin D
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Figure 8. Regulation of transcription factors during osteoblastogenesis [85].
Many hormones such as PTH, estrogens, glucocorticoids and vitamin D control bone 
formation by regulating the expression of transcription factors in osteoblasts. For 
example PTH promotes bone formation through phosphorylation and activation of 
Runx2, resulting in activation of osteoblast genes [110]. Estrogens favour 
osteoblastogenesis by activating Runx2 and /or Wnt/beta-Catenin-mediated osteoblast 
survival [111]. The Wnt signalling pathway is only relatively recently known to be 
involved in bone metabolism. Wnt signalling plays a widespread role in skeletogenesis
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from embryonic skeletal patterning, through fetal skeletal development, and bone 
remodelling in adults. Finally both growth hormone (GH) and vitamin D upregulates 
Runx2 expression, thus favoring osteoblastogenesis [112],
In addition to hormonal factors, most growth factors control osteoblastogenesis by 
modulating transcription factors expression and/or activity.
Notably, bone morphogenic protein BMP-2 promotes Runx2 expression in 
mesenchymal osteoprogenitors [113]. It also promotes Osx expression in osteoblastic 
cells.
Although transforming growth factor-p (TGFp) was found to inhibit Runx2 activity in 
vitro TGFp promotes bone formation in vivo by increasing Runx2 and decreasing 
PPARy2 expression [114]. Another anabolic factor, insulin-like growth factor-1 (IGF-1), 
promotes Osx in osteoblastic cells. The anabolic factor fibroblast growth factor-2 (FGF- 
2) increases Runx2 phosphorylation and activity. Consistently, activation of FGF 
receptor 2 (FGFR2) expression or signalling results in increased Runx2 expression and 
enhanced osteoblast differentiation [115]. The in vivo anabolic effects of PGE2 on bone 
formation are also associated with increased expression of Runx2 [116].
Finally, anabolic Wnt proteins, such as Wnt3a and WntlO, upregulate Runx2 
expression by activating the Wnt/p-Catenin pathway. Additionally, Wnt signalling 
stimulates osteoblastogenesis of mesenchymal precursors by suppressing C/EBP and 
PPARy [117]. Thus, the action of these regulatory factors on osteoblastogenesis is 
likely to be mediated at least in part by modulation of transcription factors.
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1.4. Dioxin and bone
It has been suggested that endocrine disrupters could contribute etiologically not only 
to reproductive-related disorders but also to disorders involving non-reproductive 
tissues, such as brain and skeleton, whose safety is regulated by endocrine system. 
Exposure to endocrine-disrupting chemicals, such as dioxins, may represent a risk 
factor for bone development and diseases, given that the incidence of osteoporosis is 
rising in the Western world [118], and experimental data shows that organochlorines 
have adverse effects on bone quality [119].
Bone development and homeostasis are controlled by a complex interaction of several 
hormones and vitamins [120], whose balance can be disturbed by low levels of dioxin, 
so bone may well be a target for the effect of TCDD.
Rather recently, it has been reported that in vivo, long-term exposure to TCDD dose 
dependently interferes with bone growth, modelling, and mechanical strength in adult 
rats [121].
Similarly, exposure of pregnant rats to a single dose of TCDD resulted in altered bone 
geometry, mineral density, and mechanical strength in the offspring [122]. In addition, 
the both studies suggested that the AHR plays a role in modulating the effects of 
dioxins on bones, because dioxin-resistant rats carrying a deviant aryl hydrocarbon 
receptor (AHR) were more resistant to TCDD-induced bone effects than wild-type rats. 
Interestingly, these bone effects were observed at doses of relevance for 
environmental health risk assessment [121,122],
Furthermore, data from in vitro studies suggest that proliferation of osteoprogenitor 
cells and their differentiation into mature bone cells can be target of TCDD.
It has been shown that in osteoblasts isolated from neonatal rat calvaria, 1 nM TCDD 
significantly reduced alkaline phosphatase enzymatic activity and this reduction was 
shown to occur by an AHR-dependent mechanism [123]. Furthermore, data from in
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vitro studies showed that TCDD suppresses differentiation of normal diploid rat 
osteoblasts [124]. Another AHR ligand, 3-methylcholanthrene (3MC), also inhibited 
differentiation and proliferation of rat and mouse osteoblastic cells [125]. These 
observations are in accordance with recent data indicating that TCDD exposure 
hampers matrix maturation [126].
Despite these studies, the detailed mechanisms of TCDD-induced bone effects are still 
unknown.
In the view of the current lack of information on these mechanisms, it would be 
appropriate to investigate this aspect further. Althought several experimental 
approaches are possible teh present study has used proteomics. It is therefore timely 
to consider this technology and how it might be applied to gain more information on 




1.5.1. Proteomics in the field  o f toxicology: toxicoproteomics
Proteomics refers to the study of the proteome, which is the total protein complement 
of a genome. It is presently considered to be the key technology in the global analysis 
of protein expression and in the understanding of gene function and regulation in the 
postgenomic era [127].
Proteins are cell- and tissue-specific and are affected by age, disease and trauma. Thus 
proteomes are temporally and spatially dynamic, with each analytical profile 
representing a unique moment in time. The scope of proteomics is broad; it 
encompasses identification and quantitation of proteins in cells, tissues, and biological 
fluids; analysis of changes in protein expression in normal versus diseased cells or 
between cells grown under different conditions; characterization of post-translational 
modifications; and studies of protein-protein interactions [128-130].
Toxicoproteomics uses the discovery potential of proteomics in toxicology research by 
applying global protein measurements technologies to biological samples after 
exposure to injurious agents.
Expression analysis at the protein level is a powerful new tool in toxicology, which 
allows the simultaneous identification of multiple proteins that are up- or down- 
regulated in response to a toxic event, thus providing a global perspective about how 
an organism responds to a specific toxicant. This information can define cellular gene 
and protein networks, identify target molecules of toxins, and provide future 
biomarkers and novel testing procedures.
Toxicoproteomics seeks to discover critical proteins and pathways responding to 
adverse chemical exposures and environmental stressors, in order to provide new 
toxicity signatures. In toxicoproteomics, the full range of proteomics methods and
48
Introduction
technologies are used to uncover the cellular and subcellular mechanisms at work in 
response to exposure to xenobiotics.
However, the use of toxicoproteomics in environmental sciences as a means for 
understanding toxic response and mechanisms is still relatively undeveloped, but has 
the potential to revolutionise our ability to characterise hazards [131-134].
1.5.2. Introduction to proteomic analysis
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Figure 9: Proteomic workflow
It comprises four main steps: (1) sample preparation, (2) separation of the proteins by 
two dimensional gel electrophoresis (2-DE), (3) differential gel image analysis and 
statistical analysis, (4) in gel digestion and extraction of peptides (5) identification of 




Both 2-DE and mass spectrometry analysis have been very successfully employed, but 
need appropriate statistical analysis and sophisticated bioinformatics tools to minimize 
2-DE experimental artefacts and avoid false positives or negatives in MS/MS protein 
identification [135-137].
1.5.2.1. Sample preparation
Appropriate sample preparation is absolutely essential for good 2-DE results. Due to 
the great diversity of protein sample types and origins, the optimal sample preparation 
procedure for any given sample must be determined empirically. An efficient and 
reproducible method is essential to get reliable analysis results.
Ideally, the process will result in the complete solubilization, disaggregation, 
denaturation, and reduction any disulphide bonds of the proteins in the sample. To 
fully analyze all intracellular proteins, the cells must be effectively disrupted. Choice of 
disruption method depends on whether the sample is derived from cell suspensions, 
solid tissue, or other biological material, and whether the analysis is targeting all 
proteins or just a particular sub-cellular fraction. Moreover the protein sample should 
be protected from proteolysis during cell disruption and subsequent preparation.
1.5.2.2. Two-dimensional get electrophoresis
2-D electrophoresis, introduced by O'Farrell in 1975, is a powerful and widely used 
method for the analysis of complex protein mixtures extracted from different biological 
samples. This technique separates thousands of proteins simultaneously according to 
two independent properties in two discrete steps.
The first-dimension step, isoelectric focusing (IEF), separates proteins according to 
their isoelectric points (pi). Proteins are amphoteric molecules; they carry either 
positive, negative, or zero net charge, depending on the ionisable groups present and
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the pH of their environment. The net charge of a protein is the sum of all the negative 
and positive charges of its amino acid side chains and amino- and carboxyl-termini. 
The isoelectric point is the pH at which the net charge of the protein is zero. Proteins 
are positively charged at pH values below and negatively charged at pH values above 
their pi. Under the influence of an electric field, a protein will migrate to the position in 
a pH gradient where its net charge is zero. This is the focusing effect of IEF, which 
concentrates proteins at their pis and allows proteins to be separated based on very 
small charge differences. The development of immobilized pH gradients (IPG-strips) for 
the first dimension of 2-DE, pioneered by Gorg el al. [138] made 2-DE the most useful 
and suitable tool to separate thousands of proteins simultaneously.
The second-dimension step, sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), separates proteins according to their molecular weights (Mr, relative 
molecular mass). Proteins will thus migrate to a co-ordinate on a 2D gel defined by 
their molecular mass and pi. Thousands of different proteins can thus be separated, 
and information such as the protein pi, the apparent molecular weight, and the relative 
amount of each protein can be obtained.
Visualization of the proteins after their separation can be done with different staining 
techniques. Organic dyes like Coomassie R250 or Coomassie G250 (colloidal 
Coomassie) are widely used. Coomassie staining has a linear response of three orders 
of magnitude but it suffers from a low detection sensitivity in protein, though the 
colloidal version is somewhat better in this respect [139]. Despite this limitation, 
colloidal Coomassie is still widely used, because of its low price, ease of use and 
compatibility with most subsequent protein analysis and characterization methods. 
Other methods include silver staining, which is generally more sensitive, though 
individual proteins are quite variable in their response and the range of linearity is 
rather limited. Some silver staining protocols have poor compatibility with subsequent 
MS analysis [140]. Fluorescent dyes such as Sypro Ruby, have a sensibility that is
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comparable to silver staining but their response is linear over a greater range of 
protein concentration (at least three orders of magnitude [141]). Being end point 
stains the protocol is very simple, and they are highly compatible with in gel digestion 
and mass spectrometric analysis [142] but they are unfortunately rather expensive.
1.5.2.3. Computer assisted 2-DE image analysis
The reliable evaluation and comparison of the complex 2-DE patterns by eye is 
problematic. Therefore the gel images have to be converted into digital data with a 
scanner and analysed by image analysis software. For an optimum computational 
analysis it is important to obtain a high resolution grey scale image ideally with a bit 
depth of 16 to maximise the number of distinguishable grey levels, so maintaining 
dynamic range.
The success of differential expression analysis depends critically on the accuracy and 
the reliability of the analytical software used for image processing. The software and 
the parameters chosen may have a profound effect on the interpretation of the protein 
pattern obtained and the amount of user intervention demanded during the analysis 
[143].
Currently, several 2-DE image analysis software packages are commercially available. 
These programs have been continuously improved and enhanced over the years in 
terms of faster matching algorithms with less manual intervention and with focus on 
automation. Novel algorithms offering more reliable spot detection, quantitation and 
matching have been introduced together with the inclusion of flexible statistic tools for 
a more robust differential expression analysis. This is the case of the state-of-the-art 
image software PG240 and Same Spots (NonLinear Dynamic, UK). These programs 
provide fully automated gel image processing (spot detection, gel alignment, spot 
matching and spot quantification) at the pixel level, along with sophisticated data
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visualization and downstream analysis tools. More details on their characteristics and 
their use are reported on the Material and Methods section (.section 3.10) [143-145].
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1.6. Protein identification by Mass-Spectrometry
1.6.1. Principles o f Mass Spectrometry
Mass Spectrometry is an analytical technique that measures the mass:charge ratio of a 
charged species based its response to electric and /  or magnetic fields. The sample 
molecules are converted into positive or negatively charged gas phase ions and are 
separated according to their mass to charge (m/z) ratios [146,147].
As shown in figure 10, mass spectrometers consist of three basic components, an ion 
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Figure 10. A schematic indicating the main regions of a mass spectrometer, and indication principle 
ionization methods and types of mass analyser.
The ion source converts sample molecules into ions in gas phase and one or more 
mass analysers separate the various ionised species according to their m/z ratio, while 
the detector records signal intensity at each m/z value. Conventionally, mass spectra 
are presented as a plot of m/z value against relative intensity.
Currently, the two most common ionisation methods used in the analysis of peptides 
and proteins are matrix assisted laser desorption ionisation (MALDI) and electrospray 
ionization (ESI); the latter was almost exclusively used in my studies.
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A number of different types of mass analysers are employed in proteomic research, 
and they are listed in figure 10.
Different types of mass spectrometers used in proteomics differ in their physical 
principle, their performance standards, their mode of operation and their ability to 
support specific analytical strategies [148-150].
In this thesis, two different mass spectrometers were utilised for protein identification, 
in order to take advantage from their complementary qualities: the first one used was 
the ESI-n" (ion trap) MS/MS (figure 11 A), ESI Q-TOF (quadrupole-time of flight) MS/ 
MS (figure 11 B) whose components will be described more in detail below.
Figure 11. (A) An overview of our Agilent 1200 LC/MSD Trap XCT. (B) A representative image of the 
Waters Micromass Q-ToF micro Mass Spectrometer.
Mass spectrometry based proteomics fall into two different families, top down and 
bottom up [150,151].
In the top-down approach, intact protein ions are introduced into the gas phase and 
their masses are measured, often at high accuracy with, for example, a Fourier 
transform spectrometer, providing the molecular mass of the protein. Subsequent 




In the more widely used bottom-up approach, proteins are digested with a proteolytic 
enzyme, and the resulting peptides are analyzed in the gas phase by mass 
spectrometry (MS) or by tandem mass spectrometry (MS/MS).
In MS analysis, the masses of the intact peptides are determined and protein 
identification relies upon a comparison of the experimentally determined MS peak mass 
values with the predicted molecular mass values of the peptides generated by a 
theoretical digestion of each protein in a database (peptide mass fingerprinting).
In MS/MS analysis, peptide ions are separated in a first mass analyser. Selected parent 
ions are fragmented and the fragment ions are separated in a second mass analyser to 
produce information on the sequence of the peptide. The resulting tandem mass 
spectra are compared with computer generated fragmentation models derived from all 
the tryptic peptides computed from the entries in a protein or translated nucleic acid 
database.
1.6.2. Protein cleavage
Most strategies for protein identification by mass spectrometry require proteins to be 
proteolytically cleaved into a mixture of shorter peptides which fall within the operating 
mass range of the spectrometer. This is especially the case for 2D gel based 
workflows, as used in the present studies, since in gel digestion provides a simple and 
efficient way of recovering the stained gel-entrained protein for subsequent 
characterization by MS.
The most widely used enzyme is trypsin, which hydrolyzes the protein on the C- 
terminal side of lysine and arginine, unless the following amino acid is proline. This is 
advantageous as every peptide other than the one including the original C terminus 
has at least two sites for efficient protonation, the N-terminal amino group and the C-
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terminal basic residue, so peptides are readily ionized and detected as positive ions. 
Moreover the presence of a basic residue at the C terminus favours simple and easily 
interpretable fragmentation pathways in CID experiments (see below).
1.6.3. Sample introduction into the mass spectrometer
The method of sample introduction will depend of the complexity and purity of the 
sample, and the mode of ionization employed. Well desalted samples, containing 
relatively few components of reasonable abundance may be infused directly; in most 
cases however online liquid chromatography is the favoured introduction method, 
particularly in the case of ESI, which, as an atmospheric pressure, solution phase 
technique is intrinsically compatible with liquid chromatography.
The studies reported in this thesis used mainly reversed phase liquid chromatography 
(RP-LC). In this technique the stationary phase is non-polar with respect to the mobile 
phase and hydrophobic interactions are the main mechanism of analyte retention on 
the column. The RP-LC columns most commonly used in peptide separations are 
packed with a stationary phase in which non-polar C18-alkyl chains are covalently 
attached to silica particles.
Reversed phase chromatography usually achieves a considerable improvement in the 
concentration of samples entering the ionization source, since relatively large volumes 
of dilute sample in aqueous solution can be pumped through the column, with the 
analytes of interest being initially retained as a narrow band at the top of the column, 
and components being sequentially eluted as the proportion of organic solvent in the 
mobile phase is increased. This concentration effect is enhanced by columns of small 
bore as the same amount of sample will be eluted in a lower volume. The use of nano­
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scale LC columns with internal diameters (i.d.s) of 75 pm or less has dramatically 
improved the sensitivity of analysis of complex biological samples [152].
The signal to noise ratio is generally further improved because most ionic buffers and 
inorganic salts are not retained on RP columns, and so can be diverted to waste. 
Reversed phase chromatography generally increases the number of peptides detected 
in complex mixtures, because fewer separate components enter the source at any one 
time, so the duty cycle of the spectrometer is likely to be more efficiently exploited.
1.6.4. Ion sources
The spectrometers used in my studies were both equipped with electrospray ionisation 
sources.
ESI was first described by Dole and was developed as a practical ionization source for 
mass spectrometry, initially on quadrupole instruments by John Fenn [153]. The 
mechanism of electrospray is visualized in figure 12. It is an atmospheric pressure 
ionization technique in which sample solution is sprayed from a fine capillary (usually 
around 10pm in diameter) which is maintained at a high potential difference with 
respect to the ion source orifice of the spectrometer.
This voltage is applied either via direct contact with an electrode, or through a 
(metallic-) coating on the spray tip. The potential difference generates a force 
extending the liquid to form a cone at the capillary tip (the Taylor cone) from which a 
fine mist of electrically charged droplets emerges. Positive charge is conferred by the 
presence of protons, or other cations.
These droplets rapidly become smaller, due to evaporation of solvent molecules until 
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Figure 12. Schematic of ESI (from web sources).
There are two mechanisms proposed for the desolvation and charging of analytes 
within the droplets: ion evaporation and charge residue models (IEM and CRM, 
respectively).
The IEM was the first mechanism to be proposed. This model states that when the 
droplets become smaller, the electric field will become strong enough to expel ions into 
the ambient gas. Evaporated ions can remain somewhat solvated. This model applies 
mainly to small ions.
For the ionization and evaporation of proteins, i.e. considerably large ions, the CRM is 
more applicable. In this model large droplets dissociate via a sequence of Rayleigh 
instabilities, called Coulombic explosions, into successively smaller ones until eventually 
only one analyte molecule per droplet remains. Further evaporation of solvent results 
in fully desolvated charged protein molecule. The charges are statistically distributed 





The mass spectra reported in this thesis were obtained using either a Micromass Q-ToF 
or an Agilent LC MSD or a spectrometer. These systems employ time of flight, 
quadrupole or quadrupole ion trap mass analysers.
1.6.5.1. Quadrupole mass analysers
The quadrupole mass analyser separates ions according to their m/z ratio by utilising 
the stability of their trajectories in an oscillating electrical field. Ions that do not have a 
stable trajectory through the quadrupole are ejected from the device and do not reach 
the detector.
The electric fields are provided by applying DC and radiofrequency voltages to opposite 
pairs of parallel hyperbolic rods (figure 13).
If  the DC voltage is removed, and the quadrupole is operated in radiofrequency only 
mode, it functions as a wide band pass filter, and all ions are transmitted. Application 
of the DC voltage enables transmission of a selected mass, and scanning of the DC 




ionization process of mass separation of ions
neutral molecules according to the m/z ratio
detection of 
selected Ions
ion source and 
transfer optics
ion detector and 
amplifier
Circuit diagram of the four 
quadruple rods with 
RF voltage V-costot 
and the superimposed 
DC voltage U
Figure 13. Operating principle of a Quadrupole Mass Spectrometer (from web sources).
1.6.5.2. The Quadrupole Ion trap
The quadrupole ion trap is based on the same theory as quadrupole analyser, with the 
electric fields generated within a three dimensional trap composed of a toroidal (ring) 
electrode, to which the RF voltage is applied, and two end cap electrodes creating the 





















The trap is filled with helium and the ions in the trap describe mass-dependant orbital 
trajectories governed by the RF voltages and the cooling effects of collisions with the 
helium gas.
Mass spectra are acquired by sequentially ejecting ions from low m/z to high m/z, by 
scanning the RF voltage such that sequential ion trajectories become unstable. A 
product ion MS/MS spectrum is obtained by resonance excitation. The precursor ion is 
isolated by the application of a waveform signal to the endcap electrodes. 
Fragmentation of the precursor ion can be enabled by the application of a small 
voltage across the endcap electrodes.





Figure 15. A Schematic of a Time-of-Flight mass spectrometer operating in Reflectron Mode (from web 
source University of Bristol).
In a time of flight (ToF) mass analysers, an accelerating voltage propels ions into a 
time of flight tube, where they drift towards a detector. Since ions arrive in the drift tube 
with similar kinetic energy (equal to l^m v2), ions of different mass must have 
correspondingly different velocities, the heavier ions travelling more slowly. 
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enables calculation of velocity and so mass also, since flight time is proportional to the 
square root of the m/z value.
Theoretically mass resolution should be better with a longer flight tube, so ToF 
analysers often incorporate a reflectron (ion mirror) to reverse the trajectory of the 
ions back down the flight tube, effectively increasing the distance they traverse. 
Reflectrons also improve resolution by compensating for small differences in kinetic 
energy of ions of the same mass.
1.6.5A. Q-ToF
The Q-ToF is a hybrid instrument that combines a quadrupole mass filter with a 
reflectron ToF analyser, thereby providing an MS/MS capability. A collision cell, 
containing argon, is located between the quadrupole and the ToF analyzer to induce 
fragmentation (see below) in MS/MS experiments. The quadrupole, when operated in 
RF only mode acts as an ion guide allowing MS operation, and as mass selective device 
in MS/MS mode when the DC voltages are applied. The time-of-flight (ToF) analyzer is 
placed orthogonally to the quadrupole and serves as a mass resolving device for both 
MS and MS/MS modes. This provides high sensitivity, since ToFs, being non-scanning 
devices, detect all masses in the spectrum in parallel at high acquisition rates
1.6.6. Tandem Mass-Spectrometrysignificance
Typically electrospray ionization produces little spontaneous fragmentation, so to 
obtain structurally informative tandem mass spectra (MS/MS) additional fragmentation 
must be induced artificially. Various dissociation methods to fragment ions are used, 
but gas phase collision-induced dissociation (CID) remains the commonest.
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In a Q-ToF or ion trapping instrument, the process of CID involves multiple low-energy 
collisions of the peptide precursor ion with an inert gas, which converts translational 
energy into vibrationally excited states eventually resulting in bond cleavage. The 
fragments produced are the result of N-terminal and C-terminal fragmentations across 
the peptide bond to give sequence ions with charge retention on either the acylium 
fragment, which retains the original /^terminal residue (b-type ion) or ammonium (VO 
ion fragments retaining the C-terminus. (figure 16, "peptide nomenclature7') [154]. 
Tryptic peptides by definition have readily protonated arginine or lysine residues at the 
C-terminus, which favours charge retention on the C-terminal containing fragment, so 
usually Y-type ions predominate in their low energy CID spectra, though internal lysine 
or arginines resulting from incomplete tryptic cleavage, or histidines towards the N- 
terminus, can increase the incidence of B-type cleavages. Instrument type and 
geometry can also exert a significant influence on detailed fragmentation patterns 
[155].
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Figure 16. Fragmentation nomenclature.
Additional fragments attributable to loss of water or ammonia from these ions are 
commonly observed; thus b-ions can eliminate carbon monoxide forming a-ions. 
Immonium ions (H2N=CHR, where R is the amino acid side chain) are also seen in the 




1.6.7. Protein identification and database searching
The use of MS/MS and CID is becoming the accepted standard for protein identification 
and is steadily replacing peptide mass fingerprinting. The final stage is identification of 
proteins by searching the tandem mass spectra against a protein database. Computer 
search algorithms assign sequences to the lists of mass/intensity data from each 
acquired mass spectrum. These algorithms typically compare experimental mass 
spectra with theoretical ones generated in si/ico from peptide sequence strings in 
protein databases {e.g. Swiss-Prot/UniProt).
Scores are assigned using statistical and/or probabilistic methodologies {e.g. Sequest, 
Mascot, Phenyx) which provide an estimate of the likelihood of the match originating 
by chance alone. The sequence with the highest score is assigned as the identification. 
The identified peptides are then used to derive their parent proteins. Although different 
search engines process the same input spectra and often produce comparable outputs, 
subtle difference remain [156].
The Phenyx search engine was primarily used in these studies. This applies a two- 
stage analytical strategy (see table 4 in Material and Methods section). The initial 
search typically uses stringent parameters with an extended database to obtain a 
filtered list of candidate proteins while minimising the computational overhead 
associated with too many combinatorial possibilities. In the second round a much more 
comprehensive search is performed on a limited database consisting only of the 
candidate proteins. This can encompass non-specific cleavages and consider a wide 
selection posttranslational and artefactual modifications. A search of a randomized 
version of the database enables estimation of the false-positive rate. The final
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assignments and associated confidence levels calculated from the scores and the 




The increasing body of data derived from global gene and protein expression 
measurements necessitates the use of computational technologies to store, analyze, 
interpret and learn from this information.
A number of different pathway databases and network building tools are now available, 
enabling the visualization of cellular components as networks of signalling, regulatory 
and biochemical interactions. Although most of these techniques were developed to 
accommodate the huge amount of data derived from gene microarray experiments, 
more recently they have been applied to proteomic data.
The interpretation of proteomic profiles is however a difficult task, as even simple 
stimuli can result changes in abundance of many proteins, although typically proteomic 
datasets are still smaller than those from gene microarray experiments. Many of the 
proteins that change in relative abundance may seem unconnected to the originally 
stimulated pathway. Thus, mapping of up- and/or down-regulated proteins onto known 
pathways, combining functional enrichment and transcription regulation analysis, might 
provide information to supplement the conventional approach of linking proteins to 
biological process via review of the literature. This may enable a richer interpretation of 
proteomic experiments and in the generation of new mechanistic hypotheses.
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CHAPTER 2 
AIMS OF THE THESIS
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2,3,7,8-Tetrachlorodibenzo-^-dioxin (TCDD) is considered to be one of the most potent 
toxicants known and is the prototypical representative of the polyhalogenated aromatic 
hydrocarbon class of persistent environmental contaminants. Exposure to TCDD 
produces a wide variety of species- and tissue-specific effects including endocrine 
disruption [6, 10, 16, 157]. Recently, it has been suggested that endocrine disrupters 
could contribute etiologically not only to reproductive-related disorders but also to 
disorders involving non-reproductive tissues, as bone, whose homeostasis is tightly 
regulated by endocrine system [61]. While a broad range of dioxin toxicities have been 
well documented, its effects on bone are still poorly known. Only a few experimental 
studies have demonstrated that bone development and homeostasis are targets for 
TCDD [121, 158], although the mechanistic basis of this action is far from clear. Most 
of the studies on TCDD-induced changes in bone cells have been conducted on a 
protein-by-protein basis and a limited number of proteins [159, 160]. However the 
complex interactions among growth factors, hormones, cytokines, intracellular 
signalling pathways determining osteoprogenitor cell differentiation and bone 
remodelling call for more holistic view that can be provided by integrating a proteomic 
approach. Proteomic analysis offers great opportunities for its ability to focus on 
simultaneous changes of a large number of proteins, which can reveal the complex 
interplay of different pathways at a single time-point.
The main purpose of this study was to investigate the possible disturbance of TCDD on 
bone development, focusing on osteoblastogenesis, using a proteomic approach. 
Toward this end, a model of rat mesenchymal stem cells differentiating to osteoblasts 
has been chosen, being a well-documented system for studying the molecular 
mechanism of osteogenesis in vitro.
The main objectives of this thesis were as follows:
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• monitor the time-course progression of osteoblast differentiation using well known 
osteogenic markers and verify that the cell culture model was sensitive to TCDD 
and therefore useful for this study.
• determine whether TCDD affected the proteome profile of differentiating 
osteoblasts by using a global proteomic approached based on two-dimensional gel 
electrophoresis, computerized gel image analysis, in-gel digestion, and mass 
spectrometry
• determine how protein abundance changes evoked by TCDD exposure correlated 
with alterations in biochemical indices of osteoblast activity and differentiation, in 
an attempt to gain further insight into the molecular mechanism involved in TCCD's 








2,3,7,8-TCDD was purchased from the UFA-Oil Institute (Ufa, Russia) and was found to 
be over 99% pure by gas chromatography mass spectrometry. It was dissolved in 
dimethyl sulphoxide (DMSO). All chemicals and solvents used were of the highest 
purity available.
3.2. Mesenchymal stem cell isolation and osteoblast differentiation
Cell culture was performed in collaboration with KTL Institute, National Public Health 
Institute, Finland.
Mesenchymal stem cells (MSCs) were isolated from the bone marrow of femurs and 
tibias of male Sprague-Dawley rats, 6-weeks of age. The rats were purchased from 
Harlan (Zeist, The Netherlands) and maintained at the breeding colonies of the 
National Public Health Institute, Department of Environmental Health, Kuopio, Finland. 
Animal study protocols were reviewed and approved by the Animal Experiment 
Committee of the University of Kuopio and the Kuopio Provincial Government. The 
animals were housed under controlled conditions with the temperature at 21 ± 1 °C, 
relative humidity 50 ± 10% and a 12 h lighting cycle. They had free access to tap 
water and standard pelleted laboratory animal feed R36 (Ewos, Sodertalje, Sweden). 
MSCs for one experiment were collected from 4-5 animals.
After dissecting free of adhering tissues, bones were briefly soaked in ethanol and then 
in PBS (without calcium and magnesium).
As it is shown in figure 17 the bone ends were removed aseptically in laminar hood 
and the marrow cavity was flushed out using alpha-MEM (Gibco [Invitrogen], Paisley, 
UK) medium supplemented with 7.5% fetal bovine serum (Gibco), 20 mM Hepes and
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100 U/ml penicillin & 100 pg/ml streptomycin (Gibco). After homogenization by 
pipetting up and down, the suspension was incubated for 2-3 min in order to let the 
aggregates to settle down. Supernatant was collected and centrifuged at 210xg, 5 min. 
Cells were then resuspended into mineralization medium, which consisted of enriched 
alpha-MEM supplemented with 10 nM dexamethasone (Sigma, St. Louis, MO, USA), 10 
mM glycerol phosphate (Sigma), and 50 pg/ml ascorbic acid (Wako Chemicals GmbH, 
Germany), which favour the differentiation of osteoblastic cells. Cells were counted by 
haemocytometer and plated at the density of 1 x 106 cells/cm2 in T25 cell culture flasks 
(Nunc, Roskilde, Denmark). The culture flasks were maintained in a humid atmosphere 
at 37°C with 5% CO2.
Three days later the non-adherent cells were removed by washing the attached cells 
with PBS. New mineralization medium was added. After reaching near-confluence
(usually 6 days from the beginning of culture) the cells were detached with 0.075%
i
trypsin-EDTA (Gibco). Cells were counted and plated into 6-well plates 
(45000cells/well) or 24-well plates (9000 cells/well).
Figure 17. Panel A: Sprague-Dawley male rat tibias were dissected free of adhering tissue.Bone ends 
were removed. Panel B: Marrow cavity was flushed out with Hepes-buffered completed alpha-MEM. Panel 





Next day the medium was replaced with exposure medium containing various 
concentrations of TCDD dissolved in DMSO (TCDD1: InM TCDD/0.1% DMSO; TCDD2: 
lOOnM TCDD /0.1%), or DMSO vehicle alone so that the final concentration of DMSO 
was only 0.1%. The first day of TCDD exposure was defined as day 0. Thereafter, 
fresh exposure medium with mineralization ingredients was supplied to cells at every 
3-4th day. Cells were harvested for different assays at timed intervals. The 
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Osteogenic induced samples were harvested at day 3-7-10 following TCDD exposure 
for proliferation assays, quantitative RT-PCR, Western blotting and proteomic analysis. 
Untreated cells and DMSO treated cells were harvested at the identical time points of 
osteogenic differentiation as control. Cells were collected by scraping, washed three 
times with ice-cold 10 mM PBS and pelleted. Pellets were shock-frozen in liquid 
nitrogen and stored at -80°C until further processing.
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3.5. Cell proliferation and calcium quantification assay
For the cell proliferation test and the determination of calcium, osteoblasts were grown 
on 24-well plates. Cell proliferation was determined by colorimetric assay using Cell 
Proliferation Reagent WST-1 (Roche) directly to cells. The Cell Proliferation Reagent 
WST-1 provides a colorimetric assay for the quantification of adherent or suspension 
cell viability and proliferation. The reagent is a sterile, ready-to-use solution that 
contains WST-1 and an electron coupling reagent diluted in phosphate buffered saline. 
WST-1 is a tetrazolium salt that when in contact with metabolically active cells gets 
cleaved to formazan by mitochondrial dehydrogenases. After a short incubation, 
absorbance at 450nm indicated the rate of WST-deavage by mitochondrial 
dehydrogenases, correlated with the number of viable cells in the culture. The darker 
the formazan dye, the greater the number of metabolically active cells in that well. 
Briefly, medium was removed and WST-1 reagent was added to wells. Cells were 
incubated for 1 h. After shaking the cell plate for 1 min the media were transferred into 
96-well-plate. The absorbance of the samples was measured using a plate reader at 
450 nm (Labsystems iEMS Reader MF, Ascent Software version 2.4.1).
For calcium assay, the cells were washed twice with PBS and then fixed then in 3% 
PFA for 15-20 min. Calcium content was measured as triplicates by colorimetric assay 
using a Ca kit (Roche). Cells were washed twice with H20 and incubated overnight with 
0.6 M HCI (on a shaker) using gentle shaking. The reagent mixture was added to the 
wells, incubated for 30 min, and absorbance measured at 546 nm using a plate reader.
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3.6. Real time Quantitative PCR
Total cellular RNA was isolated from the pelleted osteoblasts using EZNA™ Total RNA 
Kit and RNase-free DNase set (Omega Biotek, Doraville, GA, USA). cDNA was 
generated by Omniscript RT Kit (Qiagen, Hilden, Germany) using random hexamers 
(Roche, Mannheim, Germany) and used as a template for quantitative PCR analysis. 
The expression levels of Runx2, Alp and Ocn were analyzed using SYBR Green PCR 
Master Mix kits and an Applied Biosystems 7000 Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA). Standard curves were generated using isolated and 
purified PCR products produced with the same primers designed for quantitative PCR. 
PCR products were purified from agarose gels using QIAquick PCR Purification Kit 
(Qiagen) and the concentrations were determined spectrophotometrically.
PCR primers were designed using Primer Express software from Applied Biosystems 
that allowed the use of universal thermal cycling parameters. The following primers 
were used: rat GAPDH (NM-017008), atcccgctaacatcaaatgg and gtggttcacacccatcacaa; 
rat ALP (NM-013059), tgaatcggaacaacctgactga and ttccactagcaagaagaagccttt; rat OCN 
(NM-013414), aagcccagcgactctgagtct and ccggagtctattcaccaccttact; rat RUNX2 (XM- 
346016), ctccaacccacgaatgcacta and gtgagtggtggcggacatg.
Each PCR reaction was initiated with an incubation step of 10 min at 95°C to activate 
AmpliTaq Gold DNA Polymerase. This was followed by 40 cycles of denaturation at 
95°C for 15 s and annealing/extension at 60°C for 1 min. A dissociation curve was run 
to confirm the absence of non-specific amplification. Negative controls were included in 
each run. The expression levels were related to mRNA concentrations of the 
housekeeping gene GAPDH to normalize the amount of cDNA in the PCRs.
The experiments were repeated independently three times using three replicates. 
Statistical analysis was performed by the ANOVA followed by the Least Significant
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Difference test. In the case of non-homogenous variances the Mann-Whitney U test 
was used. The iimit of statistical significance was set at p < 0.05.
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3.7. Protein extraction for 2D-Gel electrophoresis
3.7.1. Set-up o f protein extraction protocol
In this project, rat mesenchymal stem cell along the osteoblast differentiation pathway 
has been chosen as a model system to compare the proteins expression between 
untreated and TCDD-exposed osteoblasts. It has to be underlined that differentiating 
osteoblasts are particularly difficult to grow. Consequently, one of the main constraints 
I had to face was the limited number of cells to work with. The set-up of an efficient 
protein extraction procedure was therefore mandatory.
I decided to start with some non-bone cell lines that, due to their immortalized nature, 
are easy to grow, to expand and can easily provide enough biological material to start 
with. I used a proteomic approach on two cell lines available in the laboratory (the 
human lung adenocarcinoma cell line A549 and the human bladder carcinoma cell line 
RT112), in order to optimise sample preparation strategy and to maximize the number 
of proteins extracted from the minimum amount of cells.
Various types of detergents and lysis buffer composition were employed to optimize 
the efficiency of the lysis and the protein solubilisation (table 3). To this purpose, urea 
and the zwitterionic detergent CHAPS were used at different molarities. Thiourea was 
used to improve solubilisation of membrane proteins. We found that the addition of the 
Zwittergent detergent further improved the extraction of more hydrophobic proteins. 
The reducing agent such as DTT was used to break any disulphide bonds and to 
maintain all proteins in their fully reduced state. This is not easily achieved because 
DTT (pKa 8.2) is lost from the basic part of the strip during the IEF run. A solution to 
this problem has been found adding the Destreak (bis-hydroxyethyl disulfide, GE 
Healthcare, Italy) reagent to the rehydratation buffer before the IEF run, instead of 
DTT in lysis buffer. Destreak reagent modifies the proteins by binding thiolhydroxyethyl
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groups to cysteinyl groups resulting in time-stable, 2D maps with improved 
reproducibility.
Table 3. Composition of different lysis buffers used.
Buffer 1 8M urea, 2% CHAPS, 100 mM DTT
Buffer 2 7M urea, 2M thiourea, 2% CHAPS, 100 mM DTT
Buffer 3 8M urea, 4% CHAPS, 100 mM DTT
Buffer 4
5M urea, 2M thiourea, 2% CHAPS, 2% Zwittergent, 100 mM 
DTT
Buffer 5 5M urea, 2M thiourea, 2% CHAPS, 2% Zwittergent
Figure 19 shows the Colloidal Coomassie Blue-stained 2-DE gels of whole cell lysate 
(200 pg) obtained using different extraction buffers.
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3.7.2. Application o f the optimized protein extraction protocol
Osteogenic induced samples were harvested at day 3, 7 10 following TCDD exposure. 
Untreated cells were harvested at each time point of osteogenic differentiation as 
control. Cells were collected by scraping, washed three times with ice-cold 10 mM PBS 
and pelleted. Pellets were shock-frozen in liquid nitrogen and stored at -80°C until 
further processing. Cell lysis and protein extraction was done using buffer 5 containing 
5M urea, 2M thiourea, 2% CHAPS, 2% Zwittergent and a mixture of protease inhibitors 
(complete, mini EDTA-free cocktail, Roche). DNA was sheared by passing the lysate 
through a 2lG1/2-gauge needle of a 1 ml syringe. Th lysate was sonicated for 3 
minutes and then incubated for 40 minutes at 4°C on a mixing wheel. Cell debris was 
removed by centrifugation at 15,000xg for 15 min, then the supernatant was aliquoted 
and stored at -80°C until further processing.
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3.8. Protein quantification for two-dimensional gel electrophoresis
Proteins extracted from total cell lysate for proteomic analysis were quantified using 
PlusOne 2-D Quant Kit (GE Healthcare, Italy). This kit is designed for the accurate 
determination of protein concentration in samples to be analyzed by 2-D 
electrophoresis. Many of the reagents used in the preparation of such samples, {e.g. 
detergents, reductants, chaotropes and carrier ampholytes), are incompatible with the 
majority of commercially available protein quantification kits.
The PlusOne 2-D Quant Kit works by quantitatively precipitating proteins while leaving 
interfering substances in solution. The assay is based on the specific binding of copper 
ions to protein. Precipitated proteins are resuspended in a copper-containing solution 
and unbound copper is measured with a colorimetric agent. The color density is 
inversely related to the protein concentration. The assay has a linear response to 
protein in the range of 0-50 pg. The absorbance of each sample and standard is read 
at 480 using water as reference.
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3.9. Two-dimensional gel electrophoresis (2-DE)
For each gel, 200 |jg of total protein were dissolved to a final volume of 250 pL in the 
re-hydration solution (5M urea, 2M thiourea, 2% CHAPS, 2% Zwittergent, 100 mM 
DeStreak and 0.5% IPG buffer pH 3-10 linear, GE Healthcare, Italy), and then applied 
on 13-cm-long immobilized pH 3-10 linear gradient strips (IPG strip, GE Healthcare, 
Italy). The strips were hydrated on an IPGphor apparatus (GE Healthcare, Italy) for 16 
h at 30 V/h, then focused for 26 h until 46,000 Vhr, according to the following 
program: rehydration 15h at 30V, 2h at 200V, lh  at 500V, 30min at 1000V, lh  of a 
linear gradient to 8000V, 5h at 8000v. After the first-dimension run, proteins were 
reduced by incubating individual strips for 15 min in a solution containing 50 mM Tris- 
HCI pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 60 mM dithiothreitol (DTT, GE 
Healthcare, Italy). Proteins were then alkylated by incubating the strips for 15 min in a 
similar solution, with DTT replaced by 100 mM iodoacetamide. The strips were 
embedded in 0.7% (w/v) agarose on the top of 1 mm-thick acrylamide gels cast at 
gradient (7.5-17.5 %). Proteins were separated by mass using electrophoresis at 10 
mA/gel. This was done overnight, at 4°C, in a running buffer composed of 25 mM Tris, 
250 mM glycine, 0.1% SDS. Gels were rinsed three times with de-ionised H20, fixed for 
1 hour in an aqueous solution with 50% methanol and 7% acetic acid, and rinsed 
three times again with de-ionised H20. Finally, gels were stained with colloidal 
Coomassie Blue (Pierce) for 4-5 hours then extensively washed with deionised H20. 
Colloidal Coomassie blue reagent utilizes the colloidal properties of coomassie G-250 
dye for protein staining on polyacrylamide gels. This unique reagent stains only protein 
and allows bands to be viewed directly on the gel during the staining process. It is 








3.10. Two-dimensional gel electrophoresis gel image analysis
Stained gels were scanned at 16-bit and 240 dpi resolution (Expression 1680 Pro, 
Epson) using same settings each time a gel was scanned and the resulting TIFF 
images were analyzed with two different image analysis packages: Progenesis PG240 
software (v2006, Nonlinear Dynamics, U.K., www.nonlinear.corrO and Progenesis Same 
Spots software (v3-2008, Nonlinear Dynamics, U.K.). Unfortunately the second one 
was only available in the lab from the beginning of 2008.
3.10.1. Progenesis PG240analysis
The Progenesis PG240 automatic analysis protocol for the thirty-six images of the gels
: ; i  ; i  j
included spot detertion, warping, background subtraction, average gel creation,
■ i
matching and reference gel modification. Detection, warping, and matching of the
! i
protein spots were done using the "combined warp and match" algorithm, which uses 
nonparametric pattern recognition clustering technique to align different gel images. 
"Total spot volumes normalization" algorithm was used to calculate each protein spot 
volume as the sum of the intensities of the pixels within the spot's boundary, minus
! ! • i
the background level within that same boundary ("Progenesis Background" algorithm),
normalized to the total spot volumes in the gel. Spot detection occurred after the
image was processed using the Intelligent Noise Correction Algorithm (INCA), which
discriminates between true signal and high noise levels. INCA assesses noise at each
pixel within an image and accurately removes this noise from all areas of the gel,
including that within spot material. The final effect is a significant improvement in spot
detection without the false positives, caused by data containing spikes, so it is possible
to derive even small changes from noisy images. Spot INCA volumes were normalized
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against the total volume of all the spots in the gel. Average gels were generated by the 
software for spot pattern comparison: they are a statistical combination of the replicate 
gels in a group, showing spot mean values with associated errors. The criteria for 
including a spot in the average gel were that any spot must be present in all replicates. 
Spot editing (spot splitting corrections and match editing) was done sparingly, and only 
on selected complex areas of the gel.
3.10.2. Progenesis SameSpots analysis
SameSpots gel image analysis consists of a fast and streamlined 2D workflow, which 
includes an innovative visual tool for highly advanced and automated image alignment. 
Here, images are first aligned by localised warping to an image selected as a master. 
Then spots are detected simultaneously across all the images leading to one spot map 
which is then overlaid on each warped gel image in the dataset leading to an identical 
spot outline across the gel series. After the alignment, SameSpots automatic analysis 
includes SameSpots detection, background subtraction, normalisation and matching. 
The result is perfectly aligned images at the pixel level, with 100% matching and no 
missing values, which radically reduces the need for editing spot detection and re­
matching. This novel method attempts to reduce the subjectivity of user matching and 
address the issue of missing values which are a problem for data analysis as many 
techniques in multivariate analysis cannot be used with incomplete datasets. Results 
are then ready for validation and statistical analysis.
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3.11. Proteomic statistical analysis
Both univariate and multivariate statistical methods were used to analyse the data. 
Univariate methods, e.g. Students t-Test, one-way ANOVA, are used to detect 
significant changes in the expression of individual proteins. Multivariate methods, e.g. 
principle components analysis, utilize all the protein spot data simultaneously, to look 
for patterns in abundance changes. The univariate approach gives strong candidates 
that have had significant changes in abundance, whilst the multivariate approaches can 
detect more subtle changes across sets of proteins that may be mechanistically 
correlated such as proteins in the same pathway. Both approaches have a role to play 
in data analysis. However, in this study the univariate approach was used primarily 
because it is currently the simplest to interpret conceptually and most commonly used 
in 2-DE gels differential expression analysis.
3.11.1. Univariate statistical approach
Statistical comparisons of the individual protein abundance in the experimental groups 
(one-way ANOVA) and between-groups comparisons (multiple comparison test, Tukey 
Kramer HSD, p<0.05) were computed using JMP v6 software (SAS Institute Inc.). 
Differences between groups were considered significant when expression fold-change 
was >1.5 and t test <0.05.
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3.11.2. M ultivariate statistical approach
The multivariate statistical approach was performed by using Progenesis Stats 
Package, an advanced statistical analysis tool integrated in SameSpots software 
(Nonlinear dynamics, UK). A complete list of all the specifications of this software is 
available at the http://www.nonlinear.com. Principal component analysis (PCA) was 
applied in order to determine if samples have the groupings expected or if there are 
any outliers in the data. PCA is a multivariate statistical analysis that allows the 
representation of the original dataset in a new reference system formed by new 
variables called principal components (PCs) and provides a simplified graphical 
representation of the multidimensional data. The results are visualized in plot of 
protein variables (loadings) and plot of samples (scores). The Stats package includes 
also Correlation Analysis and Hierarchical Clustering based on expression profile data. 
Furthermore the software provides the q-value for each tested spots. The q-value 
controls the false discovery rate (FDR) where the focus is on achieving an acceptable 




3.12. Protein identification by tandem mass spectrometry
Protein species with a significant modulation in their expression were excised manually 
from the gel under laminar flow sterilized hood to avoid keratin contamination.
Protein identification is based on the analysis of peptides generated by proteolyic 
digestion. To this purpose, the protease of choice is generally sequencing-grade 
modified trypsin, which hydrolyzes the protein on the C-terminal side of lysine and 
arginine, unless the subsequent amino acid in the sequence is a proline. This is 
advantageous as every peptide other than the protein C terminus has at least two sites 
for efficient protonation, the N-terminal amino group and the C-terminal basic residue, 
so peptides are readily ionized and detected as positive ions by mass spectrometry.
Two different in-gel digestion protocols were used: both manual procedure and robotic 
one.
Aliquots of the supernatant, containing tryptic peptides, were directly analyzed by 
tandem-mass spectrometry. Almost all protein identifications were performed using 
different types of mass-spectrometric platforms that were available in my lab at Mario 
Negri Institute (my Affiliated Research Centre) or during my stay in my supervisor Dr. 
Robin Waifs laboratory, at the Kennedy Institute, Imperial College, London.
3.12.1. Manual protein in-gel digestion
The whole procedure is carried on working in a laminar flow sterilized hood, by
1 \
wearing powder free gloves.
Briefly, excised spots were smashed into small pieces to increase the surface area of 
proteins/peptides in the solution for improved trypsin accessibility. The gel pieces were 
then washed with 100 pi water and then dehydrated with 100 pL acetonitrile twice.
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Cysteine residues were reduced incubating gel pieces 30 minutes at 56 °C with 
Dithiothreitol (10 mM DU/0.1 M NH4HC03). Spots were washed three times with 
acetonitrile and derivatized by treatment with Iodoacetamide (55 mM IAA/0.1 M 
NH4HCO3).
Gel pieces were washed three times with 0.1 M hydrogen carbonate, dehydrated three 
times with 100% acetonitrile and dried in a SpeedVac centrifuge.
Digestion buffer containing sequencing-grade modified trypsin (12.5 ng/pl Roche, 
Switzerland, 50mM ammonium hydrogen carbonate) was added, and spots were 
incubated one hour at 4°C. When the digestion buffer was absorbed by the gel plug, 
extra trypsin-containing buffer was removed. Then buffer without trypsin was added to 
ensure that the gel plugs were kept wet during the digestion process. 5 mM CaCI2 was 
added in order to stabilize trypsin action, since calcium ion retards trypsin autolysis. In­
gel protein digestion was performed over night at 37 °C.
Aliquots of the supernatant (approximately total digest volume was 20 pl/sample) were 
directly analysed by mass spectrometry.
3.12.2. Robotic protein in-gei digestion
Protein in gel digestion was performed by an automatic digestor (Genomic Solutions, 
Huntington, UK) at the Kennedy Institute, Imperial College, London. Excised spots 
were washed with 0.1 M ammonium hydrogen carbonate and with acetonitrile.
Cysteine residues were reduced with D U  and derivatized by treatment with 
iodoacetamide. Gel pieces were washed with ammonium hydrogen carbonate and 
dehydrated twice with acetonitrile and dried at 60 C, prior to addition of modified 




Spots were incubated for eight hours at 37 °C with digestion buffer.
The products were sequentially extracted with 25 mM ammonium hydrogen carbonate, 
CH3CN, 5% formic acid, CH3CN twice and with 10% formic acid, acetonitrile twice to 
obtain a total volume of 200ul. Extracts were lyophilized and were re-dissolved in lOul 
0.1% formic acid. Aliquots of the sample were directly analysed by mass spectrometry.
3.12.3 . Liquid chromatography-ESI (eiectrospray ionization)- ion trap 
tandem mass spectrometry
LC-MS/MS analysis was performed using an innovative microfluidic chip-based 
technology for nanoelectrospray, whose functionality is equivalent to conventional 
nanospray LC/MS, coupled to an ion trap mass spectrometer (Agilent 1200 LC/MSD 
Trap XCT).
To obtain concentration and separation of peptides, sample digest aliquots (6-8 pi, 
equal to one third of the total digest) were directly injected into a G4240-62001 HPLC- 
Chip (Agilent 1200 G4240A HPLC-Ghip Cube), composed by a 40 nl enrichment column 
and a 75 pm x 43 mm separation column packed with Zorbax 300SB-C18 (5 pm) at a 
flow rate of 0.3 pl/min. The mobile phases consisted in 0.1% formic acid in water 
(eluent A) and 0.1% formic acid in CH3CN (eluent B). The linear solvent gradient was 
as follow: from 5% of B to 30% of B in 28 min, then to 90% of B in 15 min and finally 
re-equilibration to 5% of B for 10 min.
The eiectrospray source operated in positive ion mode, with the following conditions: 
capillary voltage, -1750 V; Cap exit voltage 100V, skimmer voltage, 30.0 V; dry gas 
flow, 3 L/min; dry temperature, 300°C. Data were acquired sequentially in MS mode 
(scan range of 200 to 2000 amu) and in data dependent mode, automatically recording 
the MS/MS spectra of the four most abundant ions in every scan cycle. The MS/MS
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spectra were acquired with isolation width of 4 m/z and fragmentation amplitude of 
1.3V.
Tandem mass spectra were analysed using the MS/MS search engine Phenyx version
2.1 (GenBio, Switzerland) (www.phenyx-ms.com, phenyx@genebio.com), against the 
UniProt_Swiss Prot database (version 54.0). The search was enzymatically constrained 
for trypsin, and allowed for one missed cleavage site. Further search parameters were: 
no restriction on molecular weight (MW) and isoelectric point; taxonomy: Rattus 
norvegicus', fixed modification carbamidomethylation of cysteine; variable modification: 
oxidation of methionine.
Table 4 concisely restates the main submission parameters including algorithm, 
scoring models, thresholds. In parallel, the spectra were also searched against the 
National Center for Biotechnology Information non-redundant (NCBInr) database 
(4,076,784 sequences) using Mascot (Matrix Science).
For an identification to be considered valid we required that: (i) two or more peptides 
independently matched the same protein sequence, (ii) the peptide score was 
significant, typically greater than 55 {p < 0.05), and (iii) the manual interpretation 
confirmed agreement between spectra and peptide sequence. In addition, Mascot 
searches of all spectra were performed against a randomized version of the NCBI 
database using the same parameters as in the main search. In no case did this search 
retrieve more than a single peptide, and in all instances the peptide score was below 
the 0.05 significance level.
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Table 4_ Submission parameters to Phenyx MS/MS search engine.
Scoring model HCTultra
Parent charge 1,2,3 (trust=yes)
Rounds 1 2
Modifications Cys_CAM[fixed, all] Cys_CAM[fixed, all]
Oxidation_M[variable, none] Oxidation_M[variable, none]
Enzyme Trypsin_(KR_noP) Try psi n_(KR_noP)
miss. c leav .= l miss. cleav.=2
cleavMode=normal cleavMode=half cleaved
AC score 8 8
Pept thresholds score>=7.0 score>=6.0
p-value<=1.0E-6 p-value<=1.0E-5
length > = 6 length>=6
Conflict resolution none yes
Parent tol. 1.0 Da 2.0 Da
Turbo scoring tolerance=800.0ppm no
coverage > = 0 .2
series=b;b++;y;y++
Scoring m odel: refers to the algorithm that generates the score between experimental and 
theoretical masses, depending on the type of instrument.
Parent charge: refers to the charge state of the parent ions, singly-, doubly-, triply-charged
Rounds: sets of calculations on the data. A second round of calculations is used to fine-tune the results from the first round of 
scoring because only the accession numbers that fulfilled the first round criteria are processed during the second round. 
Modifications: fixed chemical/post-translational modification that occurs for every instance of the modifiable amino acid in the 
protein sequence; variable modification that may or may not occur.
Enzym e: the enzyme used to digest the protein. The error allowance for enzyme inefficiency is
included as number of sites per peptide that were not cut (Miss Geav) and as occurrence of the digestion according to the
cleavage rules (one or both ends of protein) (CleavMode).
AC score: refers to the minimum significant value for a protein's accession number score. Protein matches scoring lower than 
this value (set at 6) are rejected from the identified proteins.
Peptide thresholds: refer to three parameters (i) minimum peptide z-score, the minimum distance from a random match; (ii) 
minimum peptide p-value, the probability of a peptide match in a database occurring by chance with the associated z-score or 
better. The lower the p-value, the more significant the match; (iii) minimum peptide length, peptides with less than the 
specified number of amino acids (6) are reported in the peptide match results but do not contribute to the protein score. 
C onflict resolution, conflicts arise when the scoring algorithm can match more than one peptide with an acceptable z-score and 
p-value to a given spectrum. Phenyx resolves a conflict only if the conflicting peptide matches are of good enough quality, i.e. 
if they reach a minimum z-score and p-value. These thresholds are a function of the parent charge and are set by Phenyx. I f
the zscores and p-values are too low, then the conflict is not resolved and the matches are rejected.
Parent tolerance: parent error tolerance, the deviation allowed between experimental (observed) parent ion masses and the 
theoretical (calculated) masses, j
Turbo scoring: a procedure that accelerates the searches by pre-processing the data before 
submitting them to the main scoring calculation. A minimum percentage (20% ) of the peptide
sequence coverage by b+(b), b2+ (b + + ), y+  (y) or y2+ (y + + ) fragment series is looked for. I f  this percentage Is not 
attained, the spectrum is not submitted for further scoring.
In-depth explanations of each descriptor are available at www.phenyx-ms.com/
3.12.4, Liquid chromatography-ESI (eiectrospray ionization)-quadrupoie- 
Time o flight mass spectrometry
LC-qToF analysis was performed at the Kennedy Institute, Imperial College, London. 
Tandem mass spectra were recorded using a Waters Q-ToF instrument (Waters, 
Manchester, UK) interfaced to a Waters CapLC capillary chromatograph. Samples were 
dissolved in 0.1% aqueous formic acid, injected onto a PepMap C18 column (300 pmx
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0.5 cm; LC Packings, Amsterdam, The Netherlands), and eluted with an acetonitrile- 
0.1% formic acid gradient (5-70% acetonitrile over 20 min) at a flow rate of 1 pl/min. 
The capillary voltage was 3500 V. A survey scan over the m/z range 400-1300 was 
used to identify protonated peptides with charge states of 2, 3, or 4, which were 
automatically selected for data-dependent MS/MS analysis and fragmented by collision 
with argon. The resulting product ion spectra were transformed onto a singly charged 
m/z axis using a maximum entropy method (MaxEnt3, Waters), and proteins were 
identified by correlation of uninterpreted spectra to entries in Swiss-Prot/TrEMBL using 
ProteinLynx Global Server (Version 1.1, Waters). The database was created by merging 
the FASTA format files of Swiss-Prot/TrEMBL and their associated splice variants 
(1,768,175 entries at the time of writing). No taxonomic or protein mass and pi 
constraints were applied. One missed cleavage per peptide was allowed, and the initial 
mass tolerance window was set to 100 ppm. In parallel, the spectra were also searched 
using the MS/MS search engine Phenyx version 2.1 (GenBio, Switzerland) 
(www.phenyx-ms.com, phenyx@genebio.com), against the UniProt_Swiss Prot 
database (version 54.0).
3.12.5. Liquid chromatography-MALDI (m atrix assisted laser desorption 
ionization)-quadrupoie-Time o f Flight mass spectrometry
\ : I
The identification of some proteins was further confirmed using a different kind of 
ionization (Maldi QStar, Applied Biosystems, USA) at Dr. Robin Wait's laboratory. 
Following digestion, jl pL of each extracted peptide sample was spotted together with
1 pL 1% -cyano-4-hydroxycinnamic acid matrix (in 50% acetonitrile, 0.3%TFA) directly
I | .;
onto a MALDI target plate. The mass spectrometer was operated in the data-
! ' |
dependent mode. ! j
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3.13. Western Blot Analysis
3.13.1. Protein extraction for Western biot analysis
Cells extracts were prepared by lysing cells in the lysis buffer (Triton X-100, 1M Tris, 
5M NaCI) in the presence of aprotinin, leupeptine and PMSF as protease inhibitors, for 
40 minutes on ice. Insoluble materials were pelletted at 12,000xg for 10 minutes at 
4°C and the protein concentration was determined using a Biorad assay kit (BioRad, 
Milan, Italy).
3.13.2. Protein quantification for Western biot analysis
Proteins extracted from the Triton X-100 were quantified with a modified Bradford 
method [161] (Bio-rad Protein assay). The assay is based on the observation that the 
absorbance maximum for an acidic solution of Coomassie brilliant blue G-250 shifts 
from 465 nm to 595 nm when binding to protein occurs. Both hydrophobic and ionic 
interactions stabilize the anionic form of the dye, causing a visible colour change.
3.13.3. Western Biot analysis
Total cellular proteins (8 pg/lane) were separated on SDS-12% polyacrylamide 
resolving gels using the Mini Protean II electrophoresis system at 90V, for 2 hours 
(Bio-Rad, Milan, Italy). Proteins were transferred to nitrocellulose transfer membrane 
(Bio-Rad, Milan, Italy) using the transfer buffer (50 mM Tris, 100 mM glycine, SDS
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0.01%, 20% methanol) and the Bio-Rad Trans-blot system (55V, 2h). Blots were 
rinsed with TBS-T buffer (10 mM Tris-HCI pH 8, 150 mM HCI, 0.05% v/v Tween-20) 
and blocked in TBS-T, 5% w/v non fat dried milk (Nestle, Italy) for 2 h. After overnight 
incubation with primary antibody diluted 1:400 in TBS-T, 5% non-fat dried milk, (rabbit 
polyclonal antibodies:, Bcl2 N-19; Santa Cruz Biotechnology, USA; goat polyclonal 
antibodies: Annexin II A-15, Ran C-20, Calregulin N-19; Santa Cruz Biotechnology, 
USA; mouse monoclonal antibody: Vimentin clone V9, Sigma-Aldrich, USA; Bax B-9, 
Santa Cruz Biotechnology, USA; GAPDH 6C5; Calbiochem, Germany), blots were 
washed with TBS-T and incubated with secondary antibody at 1:1000 for lh . 
Peroxidase-conjugated anti-mouse, anti-goat or anti-rabbit IgG HRP (Santa Cruz, 
Biotechnology, USA) were used as secondary antibodies.
Blots were revealed using enhanced chemiluminescence (ECL) (GE Healthcare, Milan, 
Italy) visualized on autoradiography film (Hyperfilm ECL, GE Healthcare, Milan, Italy) 
and scanned as 14-bit images (Image Scanner II, GE Healthcare, Milan, Italy). The 
resulting TIFF images were analysed using the Progenesis software (v2006, Nonlinear 
Dynamics, U.K.). Expression data were normalized relative to GAPDH. Statistical 
comparisons of the individual protein abundance in the experimental groups (one-way 
ANOVA) and between-groups comparisons (multiple comparison test, Tukey Kramer 




Actin stress fibers ending to focal adhesions containing paxillin were visualized in cell 
cultures. The PFA-fixed, permeabilized (0.1 % (v/v) Triton-X-100 in PBS) and BSA 
treated (0.2 % BSA) cells were stained by using mouse monoclonal paxillin antibody 
(1/100; ZYMED Laboratories, San-Francisco, CA, USA) for 45 minutes on 4°C. Staining 
was carried out with secondary antibody (1/100; ALEXA Fluor 488 goat anti-mouse 
IgG, Molecular Probes, Oregon, USA) for 30 minutes at 4°C and with tetramethyl- 
rhodamine isothiocyanate (TRITC)-conjugated phalloidin (T-PHD; Sigma Chemical Co., 
St. Louis, MO, USA) for 20 minutes at room temperature (Sigma Chemical Co., St. 
Louis, MO, USA).
Confocal microscope (Zeiss LSM 510), with Axiovert 100M microscope and 25mW 
Argon and 5mW HeNe lasers (Lasos Germany) with 63x objective (IMA 1.2/water; Zeiss, 
Germany) was used to visualize the plane of attachment of the cells. The cover slips 
were mounted with glycerol PBS on objective glasses. For each culture well, 10 image 
frames (1024 x 1024 pixel frame size, pixel size 0.14 nm x 0.14 pm) were scanned 
from randomly chosen areas. The amount of paxillin and its organization in focal 
adhesions were visually evaluated from the acquired images.
This analysis was performed in collaboration with Prof. Juha Tuukkanen at the 





MetaCore (GeneGo StJoseph, MI, USA) was used to map the differentially expressed 
proteins into biological networks and for functional interpretation of protein data. 
MetaCore is an integrated software suite, based on a manually curated database of 
human protein-protein, protein-DNA interactions, transcriptional factors, metabolic and 
signalling pathways.
The list of differentially expressed proteins was uploaded as respective Swiss-Prot IDs 
to MetaCore for analysis. The biological process enrichment was analyzed based on GO 
Ontology processes. For network analysis, the shortest path algorithm to map the 
shortest path for interaction was used. Generation of sub-networks centered on 
transcription regulation was further investigated to explored up-steam regulatory 
molecules as key-nodes. Networks were automatically ranked by a P-value and 
interpreted in terms of Gene Ontology. Details for the assembly and network analysis 
processes are available at http://portalqenoao.com.
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4.1. Effect of TCDD on cell growth and differentiation
In this study, I exploited the ability of bone marrow stem cells (MSCs) to differentiate 
into bone-forming osteoblasts as a model system to study the effects of TCDD on 
developing bone.
MSCs were encouraged to differentiate to mature osteoblasts by the addition of 
dexamethasone, beta-glycerol phosphate and ascorbic acid, which are required, for the 
formation and mineralization of the extracellular matrix in the culture. As described in 
Section 1.3, differentiating osteoblasts progress through three phases: (i) an early 
proliferation period that continues for several days after confluence, with cells exiting 
the cell cycle between days 3 and 7, (ii) a period of collagen deposition and 
extracellular matrix maturation and (iii) terminal differentiation with mineralization of 
the mature matrix.
In this chapter of results, I describe how TCDD affects cell parameters and osteoblast 
activity in terms of mineralization and calcium deposition.
4.1.1. Cell proliferation and vitality
The condition of MSCs and their proliferation and differentiation were monitored 
frequently by microscopy. Cell proliferation was measured at several time points 
between three and thirteen days after TCDD exposure. After 7 days of culture, the 
proliferation rate of osteoblasts became slower, concomitantly with the progress of 
differentiation. Cells usually started to produce minerals around days 5-6, and 
eventually they became almost totally covered with minerals. As shown in figure 20, 
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Figure 20. Effect of TCDD on time-dependent cell proliferation of differentiating osteoblasts derived 
from rat bone marrow. Cells were treated with InM TCCD (TCDD1) and 100 nM TCDD (TCDD2) 
dissolved in DMSO or DMSO alone on day 0 and samples were collected 3-7-10 days later. Each point 
represents the mean ± SD of three replicates. Differences were not significant.
4.1.2. Calcium deposition
The calcium quantitation assay was performed exclusively on day 10 of exposure, since 
at this point untreated osteoblasts deposit enough calcium to be quantified. As shown 
in figure 21, the deposition of calcium by rat osteoblasts was significantly reduced by 
1 nM TCDD and 100 nM TCDD.
Figure 21. Effect of 10 days of 
TCDD exposure on osteoblasts 
calcium deposition. DMSO, 
untreated cells, TCDD1: cells
exposed to InM TCDD, TCDD2: 
cells exposed to lOOnM TCDD. Each 
bar represents the mean ± SD of 
three replicates. Asterisks highlight 
significant difference in calcium 
deposition levels (one-way ANOVA, 
Tukev Kramer HSD, d  <0.05).




4.1.3. Effect o f TCDD on cell growth and differentiation: remarks
The results indicated the usability of our in v/frz? model system utilizing differentiating 
osteoblasts when studying the effects of TCDD on bone development.
Cell viability and proliferation were not altered by TCDD exposure, even at the highest 
dose (lOOnM) for 10 days. However osteoblast functionality was altered since calcium 
deposition was inhibited by both TCDD doses.
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4.2. Effect of TCDD on time-dependent expression of osteogenic markers
During osteoblast differentiation, the patterns of expression of typical markers are 
organized temporally and sequentially: the runt-related transcription factor 2 (Runx2) 
is expressed during active proliferation, alkaline phosphatase (Alp) during matrix 
maturation and osteocalcin (Ocn) at the onset of mineralization.
Thus, I monitored the progress of osteoblastic differentiation and the possible effect of 
TCDD by measuring the mRNA levels of Runx2 (marker for the proliferation step), Alp 
(marker for the matrix maturation step) and Ocn (marker for the mineralization step) 
using quantitative RT-PCR after 3, 7 and 10 days of culture in presence and absence of 
TCDD.
As shown in figure 22, Runx2, Alp and Ocn levels in the DMSO-treated cells were 
highest on day 10. Both TCDD doses (1 and 100 nM) did not have any effects on the 
markers level at 3 and 7 days of exposure, while at 10 days they reduced significantly 
the mRNA expression of Runx2, Alp and Ocn.
4.2.1 Effect o f TCDD on time-dependent expression o f osteogenic markers: 
remarks
Expression of all measured marker characteristic for different stages of osteoblastic 
differentiation was dramatically reduced only after 10 days of TCDD exposure, 
indicating that TCDD significantly inhibits osteoblast differentiation in vitro in a dose- 
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Figure 22. Effect of TCDD on 
time-dependent mRNA




derived from rat bone
marrow. Cells were treated 
with InM TCCD (squares) and 
100 nM TCDD (triangles) 
dissolved in DMSO or DMSO 
alone (diamonds) on day 0 
and samples were collected 3- 
7-10 days later. Each point 
represents the mean ± SD of 
three replicates. Statistically 
significant differences induced 
by TCDD vs. control are 
depicted with asterisks (one­
way ANOVA, LSD test, 
p<0.05).
Days o f culture
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4.3. Differential proteomic analysis using univariate approach
To further investigate the disturbance of osteogenesis caused by dioxin, I adopted a 
proteomic approach to examine the overall protein expression profile in differentiating 
osteoblasts and to characterize alterations evoked by TCDD.
Differentiating osteoblasts, exposed to various concentrations of TCDD (1 and lOOnM) 
were analyzed at the same time points (3, 7 and 10 days exposure) as mRNA levels of 
osteogenic markers. As reported in section 4.2, during the three main phases of 
osteogenesis, the mRNA expression levels of typical osteogenic markers such as Runx2 
(proliferation), Alp (matrix maturation) and Ocn (mineralization) decreased dramatically 
after 10 days of exposure to TCDD. This prompted me to investigate firs t the proteome 
profile change at this time point, at which the anti-osteogenic potential of dioxin was 
observed. Then I focused my attention on earlier time points of exposure (3 and 7 
days), at which no effect on sequential differentiation markers expression was found. 
Differential protein expression was assessed using two-dimensional gel electrophoresis, 
computerized gel image analysis, in-gel digestion, and tandem-mass spectrometry.
In this chapter of results, I will report the comparative proteomic analysis performed 
using a univariate statistical method to detect statistical changes in the expression of 
individual proteins.
Although the enormous number of variable measured in proteomics (spots) and the 
relatively small samples number would call for a different data analysis (exploratory 
data approach), the univariate analysis is currently the simplest to interpret 
conceptually and the most commonly used in 2-DE gels differential expression analysis 
(see section 1.4.2.3).
Proteome profiles at each time point have been analysed separately, comparing the 
individual protein abundance in TCDD treated samples with their untreated counterpart
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using one-way ANOVA and correcting for multiple comparisons (Tukey Kramer HSD 
test).
4.3.1. Proteome profile of differentiating osteoblasts exposed for 10 days to 
TCDD
The protein expression pattern of differentiating osteoblasts exposed to TCDD for 10 
days was compared with their untreated counterpart using 2-DE image analysis 
software.
Figure 23 shows a typical 2-DE gel representative of unexposed osteoblasts 
(averaged from four replicates). Triangles represent protein species with lower (apex 
down) or greater (apex up) expression in TCCD-exposed osteoblasts with respect to 
unexposed osteoblasts.
Overall, 27 protein species, out of 790 visualised, showed a statistically significant 
abundance change of 1.5 times or more, as a result of TCDD exposure. Results of 
MS/MS identifications are summarized in table 4. Every protein is validally identified 
by at least one of the instrument. Detail information on peptide/protein identification is 
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Figure 23. Colloidal Coomassie Brilliant Blue-stained 2-DE gel of whole cell lysate (200 |jg proteins) from 
unexposed osteoblasts (DMSO). The average gel generated by image analysis of four replicates samples is 
shown. Triangles represent protein species with lower (down) or greater (up) expression in 10 days TCCD- 
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Figure 24 provides an overview of the expression patterns of the 27 protein species, 
whose abundance changed significantly in differentiating osteoblasts exposed to TCDD 
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Figure 24. Expression patterns for the selected proteins whose abundance changed significantly in 
differentiating osteoblasts unexposed (DMSO) and exposed to two doses of TCDD (1 and 100 nM). Each 
bar represents the average spot abundance expressed as INCA normalised volume ± SD. The vertical axis 
shows the INCA normalised spot volume. Numbers indicate the difference in protein expression (-fold). 
Asterisks highlight significant expression changes (one-way ANOVA, Tukey Kramer HSD p <0.05). Spot 
numbers are from the Progenesis image analysis results. Panel A: proteins up-regulated after ten days of 




4.3.1.1. Proteins up-regulated following 10 days o f TCDD exposure
TCDD exposure, mainly at the highest dose (lOOnM), significantly boosted the 
expression of 14 gel features (figure 24, panel A), which correspond to 9 individual 
proteins (table 5).
At least 6 spots were identified by MS/MS as vimentin (spots # 28, 40, 60, 64, 82, 83), 
a type III intermediate filament. Changes in vimentin expression have been reported in 
response to oxidative stress, suggesting a role for the vimentin network under 
condition of stress [162-164] and its involvement with signalling molecules [165, 166]. 
Some vimentin forms (spots # 28, 40, 60, 64, 82) had a smaller than the theoretical 
molecular weight, which would indicate proteolysis of the protein. The presence of 
such truncated forms might be compatible with the reported cleavage products of 
vimentin during the early phase of apoptosis [167]. Using tandem-mass spectrometry, 
I searched for vimentin-specific peptides resulting from cleavage at the two major 
caspase- sites at, Asp85 (caspase-3) and Asp259 (caspase-8)[167, 168]. I found multiple 
peptide coverage spanning 15 residues 78-400 for almost all of the six vimentin 
isoforms (figure 25). The most AAterminal of these peptides started at residue 70-78 
of the intact protein, and included the putative caspase-3 cleavage site at residue 85. 
No peptide was identified including the possible second cleavage site at residue 259, 
but multiple peptides were abundantly found downstream. Thus, as the peptide 
coverage was very similar for each of the isoforms, I was unable to find evidence of 
protease cleavage leading to the specific vimentin forms I observed.
Interestingly, further cytoskeletal components including tropomyosins (TPMs) were up- 
regulated in differentiating osteoblasts after TCDD exposure. Tropomyosins are a large 
class of actin binding proteins that regulate microfilament stability and organization by 
recruiting other regulatory proteins to actin, or alternatively, by inhibiting their binding 
[169]. Tropomyosins are derived from four genes (alpha, beta, gamma, and delta) and 
over 20 isoforms can be generated by alternative splicing. In my osteoblast population,
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the highest dose of TCDD significantly enhanced the expression of TPM 1, TPM2 and 
TPM4 isofbrms (spots # 66, 69, 80), approximately doubling them compared to 
untreated osteoblasts.
The expression of a further component of the cystoskeleton, gamma-actin (ACTG1, 
spot #96), was also almost doubled by the high TCDD dose. The cytoskeleton beta- 
and gamma-actin isoforms are ubiquitous in the microfilament system and it has been 
reported that over-expression of the beta-isoform in myoblast causes a striking 
increase in cell motility[170]. It is not yet clear whether this might be the case also for 
overexpression of the gamma-isoform. It is also not known how the expression of 
beta- and gamma-actin coordinates cell structure and functions.
The highest dose of TCDD induced the expression of valosin-containing protein (VCP, 
spot #92), a hexameric type II ATPase of the AAA family (ATPases with multiple 
cellular activities) that influences various cell functions, including endoplasmatic 
reticulum-associated degradation (ERAD) through the ubiquitin-proteasome system 
(UPS) [171].
I also observed a statistically significant increase in the expression of the heat shock 
cognate 71-kDa protein (HSPA8, spot #31), a cytosolic chaperonin whose abundance 
increased 5 fold following the high dose of TCCD.
The high dose also caused significant up-regulation of two proteasome subunits: 
PSMC2 (spot # 433), the regulatory subunit of the 26S proteasome with ATPase, which 
interacts with several basal transcription factors [172] and PSMB4 (spot #88), a beta- 













S p o t  28
H » «-v . L .. <1: $;.* . s I * I. * ;i t. T c r.• a ■ . • 4 1 K<>> « « . I • . <1 !> L > t I I M » «Io l*  vt j . w v < G i » > v o v *  i r i t . T A * L » r  v r i O t t v
*  * « s i ;«< i '•»"* » ( * L T r t w ' t
*** t •» » 3 e l 1. •* v . •* t * t (asasojacxra** <- s- > , v s t «  ^ „
Si IT 1 r k o 1. <1 » v1V R t L O I I 11 K k  ^ t * I ( WV
r t 1. t » I C ft »|J
« n v 1 e> tt v '$ **
« f K '  / i 'm d j i<Mf rm r*5 
Uu* P ► # *i r t * t
S p o t  40
> 1 I « V I L I »« M»OV» .  i  , H  . I f I > A RfV * *«, t « « * . v- •( -» c L . *rv« - O . . . IL • : k . « i i k . u f K *  l o s m n . n  L « m
< * *K j ju u  a . .A lA « « k .< u i3QE I t  J- V *  *_p a «. '  p .« « ■ « *  .  l i 1 « . .  v < < < . < , « .  ■ m  1
241 I O C  » ^ r > L T A A k » ( >  V # C O * t * V A A'301 v * * t r i t v c t'* '*  fr. # f-L-t > o « .J  */*, f* * ■ *341 ILjSlS 1 -a t> * » <J " **»«»;»»a*mi.« |n y jije ». k ■< v « » |a_j p_. j . i  *. r.*_ g • *• L E ® * 1 > *>(. B t i»_k
a» h : »flry<rr-riem y g r w y n ? *
S p o t  60
» I f I 1 V I I I I t I * « r  « < t i l  t I « r I t « 1 I r V YTi Tf c t VS LS t*JL # r I 3 I • t t V < I I *««!<
*1 V T » * » * V * t »  * 5«S- 9V»Sl . Q P*V«>f *l AI»A I » T » » * H T « It' t f l f l ' B  tpT» A h Y I r ► Vin * r 1.1 « q « *rrr| frjciHrr’vinr o <3 « * * »E^ytrry r pTrinrrnrs;. o v ooltno.a.m fc-VTO^EEZSBEK
m * * *§Ou«. *> *. * •  ^ * t a «. :* * *  *  * i - r . *.
241 > <■? t t O A O I Q K 'QMV^IOvfrVH KFOtTAAfclTP V»Qqyi*V*, ft .  t> •»«. * $ ft 4 « t W * « » ff V?l *
»i m c KZl&jutiSiltiXil *  »• t *
•tJM K l H t S l t t l '  I t l t t v l t l t  «<3Vt Mt T» ^M N » 6 L t
I"* __* t  r  (. m f  i  i i
S p o t  64
S v t r 3LAf» <a i n r c r tJR£V1£''V'YIv I V I6 fr * t> ;J 7.1 4.j
v tL a t 1 « r u fr i 1.» lu A L |) I «. I * >- V !- K 0 4
S p o t  82
thjt * v“ t ’V s'-*f I »\ ( » | T I ( P A • I
l t  1. 1 * ;c k 1 1 1 4 t ft fi *
>  c'v *< » fr -i r v ’fc «* l* » « r v* '1
Tf c *. **TV*t * O !»« V J H U  fr
» r a n\ 1 » > 
V C « Of**. AI V 
F V *Kk»At>C
 ^ fr F Ai'e-'l. !»‘r * a.£*h
S p o t  83
*3. PCMAPH<i » * » <t
v t •< i “*r&p o t  t r i o s
FJ H -T .-t.S -l * .» .4  P v.
•» t* r t ' i* *
. T . s i  I. a a u a i p » t *» niT iTJIV fflf
k r i v v t  <r< 1 ; | «»«  1 ■ 1 f»  ■$' [v p 4 i , t  k» t  *~M w tfyi.'A #kv.<j»a i l s l  fjtt ftifkijo** I <™C ‘ a" I Q ■ A r • A t vp»( f  t f m i
Df ft"v tT'i ~CY~t~r'V [ e i A L T S T H C t L  I* p^ajSL.R 31 I* *  *■ * »■ ■1 < 4 s l 1 . v 1 V t  i o 1 1 1 i 1 1 :a > i i 1 . ■ 1 1 > || .1. |  | x |  4/1 (
Figure 25. Panel (a) Rat vimentin aminoacid sequence with schematic representation of caspase-3 
cleavage site (DSVD85/F) and caspase-8 cleavage site (IDVD259/V) as reported by Morishima et al. 1999. 
Panel (b) Graphic representation of the peptide coverage found for each vimentin spot identified by 




4.3.1.2. Proteins down-regulated following 10 days o f TCDD exposure
As shown in figure 24> panel B, differentiating osteoblasts exposed to TCDD showed 
a significantly reduced expression of 13 protein species (9 individual proteins) in 
comparison to their untreated counterpart.
I identified 5 isoforms of lamin A (LMNA, spots # 8, 10, 32, 48, 414), whose 
expression levels were more than halved by TCDD at both doses. Lamin A is one of the 
major structural components of the nuclear envelope [173]. The presence of multiple 
isoforms with a similar molecular weight but a different pi, suggested the presence of 
post-translational modifications (PTM). The shift toward the acidic region of the 2-DE 
gel in the majority of these isoforms might indicate that PTM such as phosphorylation 
might have occurred. Indeed lamin A has multiple phosphorylation sites that control 
the assembly dynamics of lamins [174, 175]. Interestingly the most acidic isoform of 
lamin A (spot #414) made a significantly higher contribution (35%) to the total 
normalised volume of the sum of isoforms in TCDD-exposed osteoblasts than in non­
exposed cells (25%) (figure 26).
= 20
DMSO TCDD1 TCDD2
■  Spot 414
■  Spot 48 
Q Spot 32 
0  Spot 10 
□  Spot 8
Figure 26. Contribution of each lamin A isoform to the sum of the isoforms in osteoblasts exposed or not 
to two doses of TCDD (TCDD1: InM and TCDD2: lOOnM). Each bar represents the average contribution of 
each lamin A INCA-normalised spot volume to the total INCA-normalised volume of the sum of lamin A 
spots (mean ± SD). Asterisks indicate significant changes (one-way ANOVA, Tukey Kramer HSD p <0.05). 
Spot numbers refer to figure 23.
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Both TCDD doses reduced the expression of alpha, beta and gamma subunits of the 
hetero-oligomeric T-complex protein 1 (CCT1, CCT2, CCT3, spot # 76, 294, 38 
respectively), a molecular chaperone that assists protein folding upon ATP hydrolysis 
[176]. :
Similarly, a significant decrease was also observed in TCDD-exposed osteoblasts for (i) 
Ras-related protein RAB11A (RAB11A, spot #94), which governs endosomal trafficking, 
(ii) phosphoribosylaminoimidazolecarboxamide formyltransferase (A7IC, spot #35), a 
metabolic enzyme involved in the purine biosynthesis, and (iii) the 20S proteasome 
subunit alpha type 6 (PSMA6, spot #472).
The expression of annexin II (ANXA2, spot #90), a calcium regulated membrane 
binding-protein, appeared to be significantly reduced only by the high dose of TCDD. 
Notably, TCDD had a striking effect on a further calcium-binding protein, calregulin 
(CALR, spot #11). The expression of calregulin was 1.8- to 3.5 times lower in TCDD- 
exposed than in untreated osteoblasts. The difference between expected and 
experimental MW of calregulin observed on 2-DE gel (table 5) is not surprising, since 
the electrophoretic mobility of CALR is known to be anomalous, with the 46-kD protein 
showing 2-DE migration compatible with a molecular size of 60-kD [177].
4.3.1.3. Western Blot Analysis
Changes in the expression of some proteins identified by MS/MS were confirmed by 
Western blotting. Three proteins whose expression was low in TCDD-treated 
osteoblasts were selected for analysis: the two calcium-binding proteins annexin A2 
and calregulin and the structural component of the nuclear envelope lamin A. The 




I also confirmed the TCDD-induced increase in expression of vimentin. As shown in 
figure 27, osteoblasts exposed to TCDD had significantly higher expression of full 
length vimentin (54 kDa MW) than untreated cells, in accordance with my proteomic 
data. I also noted vimentin immunoreactive polypeptides at 48, 44 and 36 positions in 
both control and treated groups. A similar pattern of vimentin fragmentation has been 
previously associated with caspase-specific cleavage [167, 168]. However, the
j
fragmentation profile in Western blot analysis, albeit in accordance with the literature, 
was not supported by my preliminary sequence analysis by tandem mass-spectrometry 
(see figure 25). T can offer no plausible explanation for this difference. To my 
knowledge, there are no reports of direct confirmation {e.g. protein sequencing by 
mass-spectrometry or Edmann degradation) of the precise size and sequences of the 
vimentin fragments derived from caspase-cleavage.
Western blotting of cell lysates from untreated and TCDD-exposed osteoblasts was also 
used to investigate some molecular components regulating apoptosis. A balance 
between the Bcl-2 and Bax members is essential to the cell's apoptotic potential, low 
apoptotic activity often being associated with low Bax/Bcl-2 expression ratio. As shown 
in figure 27, osteoblasts exposed to both TCDD doses showed much lower expression 
of the pro-apoptotic Bax protein than their untreated counterparts. The effect on BCI-2 






DMSO T C w l 'TC002
LiSJ
DMSO TCD01 TCOD2

















DMSO TCDD* TC0G2 * 36
BAX
J I l A j i .
V .OMSO"TCOD1 TCDD2
0l O . X ]  „.{j _










Figure 27. Changes in annexin A2, calregulin, lamin A, vimentin, BAX and BCL2 protein levels in 
differentiating osteoblasts untreated (DMSO) or after 10 days of exposure to InM TCDD (TCDDI) and 
lOOnM TCDD (TCDD2) analyzed by Western blot. Protein bands in the autoradiograms were quantified by 
scanning densitometry. Expression data were normalized relative to GAPDH. The histograms show the 
band intensities from three independent experiments. Each bar represents the average normalized volume 
density ± SD. The vertical axis shows arbitrary density unit. Asterisks mark significant expression changes 
(one-way ANOVA, Tukey Kramer HSD p<0.05).
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4.3.2. Proteome profile o f differentiating osteoblasts exposed to TCDD a t 
earlier tim e points.
I have previously reported (section 4.3.1) that in differentiating osteoblasts, 27 protein 
species, corresponding to 18 individual proteins, showed a statistically significant 
change in abundance after 10 days of TCDD exposure, mainly at the highest dose 
(lOOnM). I was therefore interested in investigating the expression profile of these 27 
species at earlier times of TCDD exposure (3 and 7 days), where no effect on the 
expression of osteogenic markers was found.
4.3.2.1. Proteome profile o f differentiating osteoblasts exposed fo r 7  days to TCDD.
The protein expression pattern of differentiating osteoblasts exposed to lOOnM TCDD
for 7 days was compared with their untreated counterpart using 2-DE image analysis
:  I  i '
software. Figure 28 shows the 2-DE average gel representative of unexposed 
osteoblasts after 7 days of culture
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117 p  Figure 28. Colloidal Coomassie
97 -  Brilliant Blue-stained 2-DE gel
of whole cell lysate (200 pg 
proteins) from unexposed 
osteoblasts (DMSO). The 
average gel generated by 
image analysis of four 
replicates samples is shown.
The protein spot, whose 
abundance is significant 
decreased by 7-days of TCDD 









As shown in figure 28, only one out of the selected 27 protein species was 
significantly altered in its expression level: the abundance of calregulin (spot #11, 
p<0.01) was approximately halved by TCDD treatment.
4.3.2.2. Proteome profile o f differentiating osteoblasts exposed fo r 3 days to TCDD
The protein expression pattern of differentiating osteoblasts exposed to lOOnM TCDD 
for 3 days was compared with their untreated counterpart using 2-DE image analysis 
software. Figure 29 shows the 2-DE average gel representative of unexposed 
osteoblasts after 3 days of culture.
None of 27 monitored protein species showed any statistically significant change in the 
expression level after 3 days of TCDD exposure.
Figure 29. Colloidal Coomassie 
Brilliant Blue-stained 2-DE gel of 
whole cell lysate (200 pg 
proteins) from unexposed 
osteoblasts (DMSO) at three 
days of cell culture. The average 
gel generated by image analysis 
of four replicates samples is 
shown.
3-days of TCDD exposure did 
not affected significantly the 
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No further protein out of the monitored 27 protein species showed any change in 
abundance unique to 3 and/or 7 days of exposure.
4.3.3. Time-course analysis o f the identified proteins susceptible to TCDD in 
relation to the progress o f osteoblastic differentiation
I explored the expression profile of the identified protein species susceptible to TCDD 
effect, in relation to the progress of osteoblastic differentiation, comparing their 
expression in untreated differentiating osteoblasts at 3, 7, and 10 days of culture in 
osteogenic conditions.
As shown in figure 30, the majority of the identified TCDD susceptible proteins 
showed significant expression changes as osteoblasts differentiated.
On the basis of these changes, proteins might be grouped into 3 main classes.
The firs t class includes proteins, whose expression gradually and significantly increased 
with the progress of differentiation. Most striking was the increase in the expression of 
calregulin (spot# ll) after 10 days, compared to days 3 and 7 (9-fold, p<0.001 and 
5.5-fold p<0.01 respectively) (figure 30, panel A).
A similar pattern of expression was observed for all the lamin species, whose levels 
were higher at day 10 (spot #8, 10, 32, 48, 414, range 1.5-3-fold, p<0.001) than at
day 3 of culture. Interestingly, also the expression of annexin A2 was significantly
i
increased at day 10 relative to day3 (3-fold, p<0.01). At day 10, the expression of two 
vimentin species (spot #60, #82) was between 2 and 3 times higher than at early time
points (p<0.01). Moreover this trend was also observed for other vimentin species
■ |
(#28, #40) although it did not reach statistical significance.
Ten days of culture; significantly increased the levels of RAB11A (spot #94, 4.4-fold, 
p<0.01), ATEC (spot #35, 3.1-fold, p<0.001), and cytosolic chaperonins CCT1, CCT3
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(spot #76 and #38, 2.1-3.3-fold respectively, p<0.001), but had a less pronounced 
effect on chaperonin CCT2, whose difference in abundance did not reach statistical 
significance.
The second group of proteins includes those, whose expression gradually decreased as 
cells differentiated. TPM1, TPM2 and TPM4 exhibited a significantly reduced expression 
at day 10, compared with day 3 (spots #66, #69, #80, 2.3-, 2.4- and 1.88-fold 
respectively, p<0.001). This trend was also found for one vimentin isoform (spot #83) 
whose abundance was 1.7-fold lower at 10 than at 3 days (p<0.01).
A more pronounced decrease in abundance at the differentiation stage was also 
observed for VCP (spot #92, 2.44-fold, p<0.01) and HSPA8 (spot #31, 4.75-fold, 
p<0.001) (figure 30, panel B).
The third group includes few whose expression levels did not changes significantly in 
relation to the length of culture.
Notably, many of the observed patterns of expression accompanying the differentiation 
progress were reversed by 10 days of TCDD exposure as shown in figure 31.
This was the case for calregulin and all the lamin A species that, while increasing their 
abundance during differentiation, were down-regulated by 10 days of exposure to 
TCDD. The same was true for CCT1, CCT2 and CCT3, ATIC, RAB11A and PSMA6. 
Interestingly, all proteins within the second group (TPM isoforms, VCP and HSPA8), 
whose reduced expression was observed as osteoblast differentiated, were up- 
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Figure 30. Expression patterns of the identified protein species susceptible to TCDD effect, in relation to 
the progress of osteoblastic differentiation. Each bar represents the average spot abundance expressed as 
INCA normalised volume ± SD in differentiating osteoblasts unexposed (DMSO) at three different time 
points (3, 7 and 10 days of culture). The vertical axis shows the INCA normalised spot volume. Numbers 
indicate the difference in protein expression (-fold). Asterisks highlight significant expression changes 
(one-way ANOVA, Tukey Kramer HSD. Three asterisks indicate p <0.001, two asterisks indicate p<0.01, 
one asterisk indicates p<0.5). Spot numbers refer to figure 23. Panel A: proteins up-regulated as 
osteoblasts differentiated. Panel B: proteins down-regulated as osteoblasts differentiated.
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Figure 31. Expression levels for the selected proteins whose patterns of expression accompanying the 
differentiation progress were reverted by 10 days of TCDD exposure. Each bar represents the average 
spot abundance expressed as INCA normalised volume ± SD. The vertical axis shows the INCA 
normalised spot volume. Numbers indicate the difference in protein expression (-fold). Dots highlight 
significant expression changes by TCDD treatment (one-way ANOVA, Tukey Kramer HSD. Three dots 




4.3.4. Differentialproteomic analysis using univariate approach: remarks
Three major conclusions can be drawn from these proteomic results.
First, I have shown that at early time points of TCDD exposure, when cells are still 
proliferating (3 days) or/and enter in the differentiation stage (7 days), TCDD had no 
significant effect on proteome profile. The only exception is the significantly decreased 
expression of calregulin occurring after 7 days of TCDD treatment. Calregulin is a 
chaperone protein that regulates Ca2+ levels by modulation of the endoplasmatic 
reticulum (ER) Ca2+ storage and transport [178]. Thus, the reduction of calregulin 
might represent an early marker of the TCDD-induced disruption of calcium 
homeostasis, since calregulin is also down regulated after 10 days of exposure, at 
which time calcium deposition is significantly decreased in TCDD-exposed osteoblasts 
{section 4.1.2).
Secondly, after 10 days of TCDD exposure, at which point the osteoblasts should be 
fully differentiated, the proteome profile has been significantly altered.
TCDD strongly induced the expression of cytoskeietai components such as TPM, 
vimentin and ACTG1. All these proteins are implicated in one or more steps of 
cytoskeleton protection, stress fiber assembly and cell motility [162, 163, 179-181]. 
Interestingly TCCD down-regulated the expression of two important calcium-binding 
proteins, calregulin and annexin A2. Calregulin is a multifunctional protein that 
participates in calcium homeostasis via its high calcium storage capacity [177, 178, 
182]. Annexin A2 serves as a Ca2+ channel in the plasma membrane and in matrix 
vesicles, which have the vital role of initiating mineralization in bone [183]. Under­
expression of these proteins might therefore interfere with calcium transport and 







Further important pathways influenced by TCDD are related to protein quality control 
and trafficking. In TCDD-exposed osteoblasts there was a significant decrease in the 
expression of chaperonins containing T-complex polypeptides 1, 2 and 3 (CCT1, CCT2, 
CCT3) which assist in the folding of actin and tubulin, suggesting dysregulation of 
protein-folding and possible abnormalities in cytoskeleton organization.
The intracellular trafficking machinery of osteoblasts is also likely to be impaired by the 
down-regulation of RAB11A, a member of the large superfamily of small Ras-related 
GTP-binding Rab proteins, acting as master signal components that regulate many 
aspects of vesicular transport along recycling, endocytic and exocytic pathways. In this 
scenario, the TCDD-enhanced expression of PSMC2, a 26S subunit regulatory unit, and 
of PSMB4, the 20S catalytic/enzymatic core, together with the down-regulation of 
PSMA6, the alpha-type subunit of the 20S proteasome, although apparently 
contradictory, might be simply a sign of changes in the proteasome subunit 
composition and activity after exposure to TCDD.
The TCDD-induced up-regulation of the chaperonin HSPA8 may be an adaptive 
response to reinforce the protein-folding control process and to boost tolerance to 
stressful conditions [184].
Thirdly, I found that TCDD exposure counteracts the expression profile of proteins 
associated with the duration of culture in osteogenic conditions, i.e. associated with 
normal growth and differentiation kinetics.
Calregulin was strongly up-regulated during osteoblast differentiation, increasing 9-fold 
at 10 days of culture compared to three days. This trend is consistent with the 
reported increase in calregulin expression accompanying the differentiation of 
osteoprogenitor cells in mouse bone marrow into preosteoblast cells upon parathyroid 
hormone treatment [185]. Thus, calregulin may participate in an intracellular Ca2+ 
transport pathway and could function as a Ca2+ carrier to the mineralization front. Such
126
Results
role would be dramatically jeopardized by TCDD, which might impair the osteoblast
i
mineralization process, reducing the level of calregulin.
TCDD also reversed the expression trends of annexin A2, lamin A, RAB11A and 
chaperonins CCT1, CCT2, CCT3. These proteins showed a gradual up-regulation during 
differentiation in accordance with their functional role in growth and differentiation. In 
fact the expression trend of annexin A2 and RAB11A is consistent with their role in the 
progression of mineralization [183] and of secretory functions in differentiated 
osteoblasts [186]. Enhanced expression of lamin A is considered an early marker of 
differentiation, and it is speculated that the mechanism may involved increased nuclear 
rigidity [187]. Cytosolic chaperonins CCTs have been shown to play an important role 
in cell growth and differentiation by assisting in the folding of tubulin and other protein 
[176].
The drop of the expression levels of all these proteins caused by TCDD may thus 
impair osteogenic progression and the functionality of osteoblasts by lowering their 
secretory capacity, ability to maintain the differentiated state, protein folding efficiency 
and control of trafficking.
Cellular differentiation/ associated with phenotypic modifications of the cell, includes 
reorganization of the cytoskeleton involving changes in cell shape and cell contacts. 
During osteogenic differentiation, MSCs change from their characteristic fibroblast-like 
phenotype to a near spherical shape characteristic of the differentiated stage, with a 
consequent change in the kinetics of dynamic assembly and disassembly of 
microfilaments [188].
In my model, osteoblast differentiation was accompanied by a gradual decrease in the 
expression of tropomyosin, a major microfilament stabilizing component, consistent 
with the tropomyosin reduction reported in differentiating systems of non-muscle cells 
[189, 190]. In parallel I  observed a differential expression of type III intermediate 
fiiament vimentin spot83, which was reduced after 10 days of culture, when the
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majority of cells have changed their shape to the more rounded form associated with 
the differentiated state [185,190].
Such expected changes in cytoskeletal organization during the osteogenic 
differentiation were again reversed by 10 days of TCDD exposure, which causes 




4.4. Differential proteomic analysis using a multivariate approach for data 
assessment
Quantitative 2-DE gel data typically comprise many variables (protein species) but few 
observations (experimental replications). Multivariate analyses have been proposed to 
aid in the evaluation of proteomics experiments, since in general they cope well with 
data sets where the number of observations is much smaller that the number of 
variables [191]. Instead of analyzing each protein variable on its own (as in the 
univariate approach), all protein variables can be evaluated at the same time using 
multivariate techniques to look for patterns in expression changes. The type of 
multivariate analysis already applied to proteomic data is a method for dimension 
reduction known as principal component analysis (PCA) [192]. PCA is an unsupervised 
technique {i.e. it does not use any knowledge of the groupings of the data) which 
provides a simplified graphical representation of the multidimensional data.
Therefore I have applied PCA to my whole study as an exploratory data analysis 
method able to visualize differences between complex proteome profiles.
I used new software that has been recently obtained by my laboratory, the Progenesis 
SameSpots and Stats package (Nonlinear Dynamics, UK).
The unique approach of Progenesis SameSpots and Stats produces results with no 
missing values, so both univariate and multivariate statistical techniques can be applied 
for a complete exploration of the protein expression data. The statistics package 
includes PCA and also Correlation Analysis and Hierarchical Clustering based on 
expression profile data. Furthermore the software provides the q-value for each tested 
spots. The q-value controls the false discovery rate (FDR) where the focus is on 
achieving an acceptable ratio of true and false positives. For example, a q-value of
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0.05 (FDR = 5%) means that on average 5% of changes identified as significant would 
be expected to have arisen from type I error (a protein species is declared to be 
differently expressed erroneously). In this study, the level of significance has been set 
up at FDR<5%.
The starting point was to apply PCA with a low level of assumption, which means 
including in the analysis all the spots automatically identified as interesting in 
accordance to ANOVA p-values (p<0.05) when all treatments groups are included 
(unexposed and 2-doses TCDD exposed groups at 3, 7 and 10 days of exposure).
The visualisation of samples (group treatment) and features score (protein spots score) 
and as loading plots on PCA graph is shown in figure 32.
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Figure 32. PCA score and loadings plot of the two first PCs of the whole dataset. PCI: 46.27%, PC2: 
17.34%. Pink, light blue and purple dots refer to 2-DE gels from 3-days exposure, where pink highlights 
untreated samples, light blue TCDD InM treated samples, purple TCDD 100 nM treated samples. Light 
orange, pale blue and orange dots refer to 2-DE gels from 7-days exposure, where light orange highlights 
untreated samples, pale blue TCDD InM treated samples, orange TCDD 100 nM treated samples. Green, 
dark green and brilliant green dots refer to 2-DE gels from 10-days exposure, where green highlights 
untreated samples, dark green TCDD InM treated samples, brilliant green TCDD 100 nM treated samples. 
Numbers on the plot refer to discriminating spots number.
The first principal component (PCI) alone accounted for approximately 47% of the 
total variance contained in the original data set. It was able to separate two classes of
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samples: <0, 3 days as whole; >0, 7 and 10 days as a whole, suggesting that the data 
showed a duration effect (culture days) rather than an exposure effect (TCDD doses) 
and that the variance increases over time.
This preliminary evaluation prompted me to look exclusively within time differences 
(untreated osteoblasts culture days), excluding 2-DE gel images with TCDD doses from 
the PCA analysis,
As shown in figure 33, PCI splits the data into two main groups: <0= untreated 
osteoblasts after 3 days of culture and >0= untreated osteoblasts after 7 and 10 days 













Figure 33. PCA score and loadings plot of the two first PCs of the dataset referring to untreated samples. 
PCI: 74.95 %, PC2: 5.85 %. Pink dots refer to 2-DE gels from 3-days untreated samples, light blue to 7- 




This result was further investigated to evaluate the discriminating spots responsible for 
the clustering. These results are display in figure 34.










Figure 34. Panel A: discriminating spots location of 2-DE gel image. Red spot: proteins showing up- 
regulated expression with increasing length of culture time; blue spots: proteins showing down-regulated 
expression with increasing length of culture time. See table 6 for protein identification. Panel B: 
dendrogram tree where similar protein expression profiles cluster together. Panel C: the corresponding 
expression profiles, where red line refers to proteins showing up-regulated expression with increasing 




In figure 34, the 69 discriminating spots (FDR<5%) are highlighted on the gel image 
together with their pattern of expression. There were 8 protein species whose 
expression was up-regulated and 61 whose expression was down-regulated with 
increased culture duration.
The 74% of these spots (51 out of 69) identified by MS/MS are reported in table 6. 
The identified protein species corresponded to 34 individual proteins, whose functional 
classification is reported in section 4.6.
Among these 69 spots, there were 6 protein species that lay further away from the plot 
origin, suggesting that they had the strongest impact on the model.
In fact, when the PCA analysis was restricted to these features, PCI explained 93% of 
the variance (figure 35) and the power of the analysis was more than 80% (data not 
shown). These protein features were grouped by their expression patterns using 
correlation analysis and hierarchical clustering. One protein species, namely 
calreticulin, was up-regulated during the process of osteoblast differentiation, rising 
above the 3 days level at 10 days of culture. The remaining five (NPM1, HSPbl and 3 
isoforms of CALD) were all reduced in abundance after 7 days of culture and reached a 
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Figure 35. Panel A: PCA score and loadings plot of the two first PCs of the dataset referring to untreated 
samples. PCI: 93%, PC2: 6%. Pink dots refer to 2-DE gels from 3-days untreated samples, light blue to 7- 
days untreated samples, purple to 10-days untreated samples. Numbers on the plot refer to discriminating 
spots number. Panel B: discriminating spots location of 2-DE gel image. Red spot: proteins showing up- 
regulated expression with increasing length of culture; blue spots: proteins showing down-regulated 
expression with increasing length of culture. Panel C: similar protein expression profiles are clustered 
together using correlation analysis and hierarchical clustering. Red line refers to proteins showing up- 
regulated expression with increasing length of culture, blue line to proteins showing down-regulated 
expression with increasing length of culture. See Appendix 7.2 for full protein names.
Results
To explore further, I examined exposure differences within each time point, in case the 
cross time point effects were masking the treatment effects.
As shown in figure 36, TCDD exposure for 3 days had a relatively slight effect on the 
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FIGURE 36. PCA score and loadings plot of the two first PCs of the dataset referring to 3-days untreated 
and TCDD treated samples. PCI: 43.16%, PC2: 33.05%. Pink dots highlight 2-DE gels from 3-days 
untreated samples, light blue from 3-days TCDD InM treated samples, purple from 3-days TCDD 100 nM 
treated samples. Numbers on the plot refer to discriminating spots number.
A more obvious effect of TCDD on osteoblast proteins was observed at 7 days of 
exposure, but only when the highest dose (100 nM) was considered (figure 37). PCI 
explained 68% of the variance and the untreated samples were much better separated 
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Figure 37. PCA score and loadings plot of the two first PCs of the dataset referring to 7-days untreated 
and TCDD treated samples. PCI: 68%, PC2: 12%. Pink dots highlights 2-DE gels from 7-days untreated 
samples, light blue from 7-days TCDD lOOnM-treated samples. Numbers on the plot refer to discriminating 
spots number.
Similarly, PCA analysis showed a clearer effect of TCDD treatment when the exposure 
duration was 10 days (figure 38). At this time point, PCI explained 85% of the 
variability in the dataset, when the control group was compared with the one exposed 
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Principal Component 1
Figure 38. PCA score and loadings plot of the two first PCs of the dataset referring to 10-days untreated 
and TCDD treated samples. PCI: 85.79%, PC2: 4.87%. Pink dots highlights 2-DE gels from 10-days 
untreated samples, purple from 10-days TCDD 100 nM treated samples.
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There were 42 discriminating protein species, out of them 19 had an FDR<5%. These 
spots are shown in figure 39. Mass spectrometric identification was successful for 38 
spots (90%), corresponding to 19 individual proteins.
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Figure 39. Location on the 2-DE gel image of the 42 discriminating spots for the PCA analysis of 10-days 
exposure untreated vs TCDD lOOnM treated samples. Pink arrows highlight the protein species with 
FDR<5%. n.i. refers to unidentified proteins. See Appendix 7.2 for full protein names.
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The expression cluster of the 42 spots is shown in figure 40. There were 8 protein 
species down regulated, whereas the remaining 38 were up-regulated by the highest 
dose of TCDD. The most significantly down-regulated proteins, (FDR<5%), were 2 
isoforms of lamin A. Moreover two ATIC isoforms, CCT3, calregulin and one 
unidentified spot were down-regulated. In the up-regulated set of proteins there were 
17 with FDR<5% (two unidentified identified spots, VCP, one PDIA3 isoform, RCN2, 
tropomyosin 1 and tropomyosin 2 and ten vimentin isoforms).
The function of these proteins is reported in table 7.
1Gd TCDD2
Figure 40. Expression profile cluster of the 42 discriminating spots for the PCA analysis of 10-days 
exposure untreated vs. TCDD lOOnM (TCDD2) treated samples. There were 8 down-regulated protein 
species (blue) and 34 up-regulated proteins (red).
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Protein name Protein Function
ACTN4 Q9QXQ0 Alpha-actinin-4
F-actin cross-linking protein which is thought to 
anchor actin to a variety of intracellular structures.
ANXA1 P07150 Annexin A1
Calcium/phospholipid-binding protein which 






Metabolic enzyme involved in the purine 
biosynthesis.
CALD Q62736 L-caldesmon
Actin- and myosin-binding protein implicated in the 
regulation of actomyosin interactions in smooth 
muscle and nonmuscle cells. Stimulates actin 
binding of tropomyosin which increases the 
stabilization of actin filament structure. Interacts 
with actin, myosin, two molecules of tropomyosin 
and with calmodulin.
CCT3 Q6P502 T-complex protein 1 subunit gamma
Molecular chaperone; assist the folding of proteins 
upon ATP hydrolysis.
EMD Q63190 Emerin. Involved in stress resistance and actin organization.
ENOl P04764 Alpha-enolase
Multifunctional enzyme that, as well as its role in 
glycolysis, plays a part in various processes such as 
growth control, hypoxia tolerance and allergic 
responses.
ERP29 P52555 Endoplasmatic reticulum protein 29
Plays an important role in the processing of 
secretory proteins within the endoplasmic reticulum 
(ER), possibly by participating in the folding of 
proteins in the ER.
HSPA5 P11021 Heat shock 70 kDa protein 5 Plays a role in facilitating the assembly of multimeric protein complexes inside the ER.
HSPB1 P42930 Heat shock protein beta-1 Involved in stress resistance and actin organization.
LMNA P48679 Lamin-A.
Component of the nuclear lamina, which is thought 
to provide a framework for the nuclear envelope 
and may also interact with chromatin.
PDIA3 P11598 Protein disulfide-isomerase A3
Endoplasmic reticulum lumen protein involved in 
protein importing into nucleus and protein 
retention in ER.
RCN2 Q62703 Reticulocalbin-2 Calcium-binding protein.
TPM1 P04692 Tropomyosin alpha-1 chain Cytoskeleton element binding to actin filaments in muscle and non-muscle cells.
TPM2 P58775 Tropomyosin beta Cytoskeleton element binding to actin filaments in muscle and non-muscle cells.
TPM4 P09495 Tropomyosin alpha-4 Cytoskeleton element binding to actin filaments in muscle and non-muscle cells.
VCP P46462 Valosin-containing protein Hexameric type II ATPase with multiple cellular activities.
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This trend in the effect of TCDD exposure duration on the osteoblast proteome profile 
is in accordance with the conclusions from the univariate analysis (see section 4.3).
Cross-comparison of the protein spots highlighted by univariate and multivariate 
analysis found 47% proteins in common contributing to the discrimination of untreated 
and TCDD treated 10-day groups as shown in figure 41.
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Figure 41. Venn diagram of osteoblast proteins expressed differentially after 10 days of TCDD exposure 
using two statistical approaches. In red are proteins with FDR<5% derived from multivariate analysis.
4.4.1. D iffe ren tia l proteom ic analysis using a m u ltiva ria te  approach fo r data  
assessment: rem arks
The PCA, which considers data globally, has been applied to dataset obtained from 
multi-gel experiments to assess whether TCDD treatment (doses and length of 




Four main conclusions can be drawn from the results obtained using this alternative 
statistical approach:
1. The PCA identified particularly robust changes in the proteome profile correlated to 
a duration based effect (culture days) rather than an exposure effect (TCDD doses). 
This conclusion was unique to the PCA.
2. Despite the relevant time-effect, PCA showed that the overall proteome profile was 
statistically distinguishable between untreated and treated cells only when cells were 
exposed to the highest dose of TCDD for 10 days. This finding was in accordance with 
the univariate analysis of the same dataset.
3. A number of protein spots (47%), contributing to the separation between 10-days 
untreated and TCDD treated group, were common to the two statistical approaches. 
These proteins highlighted by both univariate and multivariate statistical analyses are 
highly likely to be significant, despite the possibility of false-positives. The presence of 
proteins not shared by both analyses underline the different conceptual basis of the 
two methods.
4. The application of these two approaches to the same dataset demonstrated their 
complementary roles for identifying spots with expression changes. As PCA identifies 
correlated changes, it is particularly useful for recognizing pathway changes and events 
correlated to each other, whereas the univariate method is more appropriate for 
identifying protein expression changes that are significant, but not directly related to 




In this project, I applied confocal microscopy to explore the role of TCDD on the 
adhesion properties of osteoblasts. Thus, it constituted a validation method for the 
proteomic findings, showing that cytoskeletal components were very susceptible to 
TCDD exposure.
Confocal microscopy offers several advantages over conventional wide field optical 
microscopy, including the ability to control depth of field, elimination or reduction of 
background information away from the focal plane (that leads to image degradation), 
and the ability to collect serial optical sections from thick specimens. The basic key to 
the confocal approach is the use of spatial filtering techniques to eliminate out-of-focus 
light or glare when specimen thickness exceeds the immediate plane of focus. Laser 
scanning confocal microscopy of biological materials relies heavily on fluorescence as 
an imaging mode, primarily because of its high sensitivity and ability to specifically 
target structural components and dynamic processes in chemically fixed as well as 
living cells and tissues.
Cell adhesion to extracellular matrices provides the environmental cues necessary to 
control a cell's decision to survive, proliferate, differentiate or migrate. Cell-matrix 
interactions generate anchorage forces that mediate cell spreading and migration. 
Adhesion to extracellular matrix components, such as fibronectin and laminin, is 
primarily mediated by integrin receptors, as shown in scheme 1. Integrin-mediated 
adhesion is a highly regulated process involving receptor activation and mechanical 
coupling to extracellular ligands. Bound receptors rapidly associate with the actin 
cytoskeleton and cluster together to form focal adhesions, discrete supramolecular
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complexes that contain structural proteins, such as vinculin and talin, and signalling 
molecules, including Focal Adhesion Kinases (FAC) and Src.
Confocal microscopy analysis was carried out in collaboration with Prof. Juha 
Tuukkanen at the Department of Anatomy and Cell Biology, Institute of Biomedicine , 
University of Oulu, Finland.
Cell adhesion was qualitatively analysed by immunofluorescence of proteins (actin and 
paxillin) participating in the attachment of cells to the substrate. Paxillin anchors the 
actin cytoskeleton and forms focal adhesions by linking actins to transmembrane 
integrins.
We examined osteoblasts double-labelled with fluorescently tagged actin to reveal the 
F-actin cytoskeleton and an anti-paxillin antibody to show focal contacts. The amount 
of paxillin (green spots) and its organization in focal adhesions were visually evaluated 
from the images.
As shown in figure 42, increased focal contact formation and a more robust stress 
fiber-containing actin cytoskeleton were evident in osteoblasts exposed to TCDD for 10 
days. The intensity of the fluorescence and the fibrillar organization were much lower 
in controls (A) than exposed cells (B and C). No apparent difference was found 






Figure 42. Effects of TCDD on focal 
adhesion complexes (paxillin stained with 
ALEXA Fluor 488, green; and actin stress 
fibers with TRTTC-conjugated phalloidin, 
red). Differentiating osteoblasts from rat 
bone marrow were either untreated (A), or 
treated with 1 nM TCDD (B) or 100 nM 
TCDD (C) for 10 days, then immunostained 
as described under Material and Methods. 
Pictures for each treatment reflect the 
typical appearance of the staining intensity 
and organization of the cytoskeleton. 
41x122mm (300 x 300 DPI)
4.5.1. Confocal m icroscopy: rem arks
Staining for the focal adhesion marker paxillin showed an increase in focal adhesion 
contacts in osteoblasts after 10 days of exposure to lOOnM TCDD. This might imply 
enhanced adhesion of exposed osteoblasts, which could interfere with/or reduce the 
differentiation processes [193]. These effects on adhesion-mediated events agree with 





The functional classification and significance of differently expressed proteins was 
evaluated by adopting a bioinformatic approach of linking known proteins to their 
putative biological functions using the MetaCore mapping tool as previously described 
(section 3.15).
Attention has been mainly focused on the differentially expressed proteins highlighted 
by univariate and multivariate analysis in differentiating osteoblasts exposed for 10 
days to TCDD.
Further interpretation of the proteomic data was carried out on the proteins whose 
abundance was significantly modulated by time differences (untreated osteoblasts 
culture days) and not by TCDD exposure (multivariate analysis).
The MetaCore software became available in the laboratory in 2008, thus my proteomic 
data were the first training set used to generate networks and to interpret 
experimental data.
4.6.1. Functional ontology enrichment
The biological process enrichment was analysed based on GO Ontology processes. 
Both univariate and multivariate analysis showed that the differentially expressed 
proteins modulated by 10 days TCDD exposure were mostly involved in cytoskeleton 
organization, actin filament-based process, protein transport and folding, as shown in 
figure 43 (panel A and B respectively).
The classification of biological processes associated with proteins whose expression 
was modulated only by the progress of osteoblastic differentiation {multivariate
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analysis) confirms that cytoskeletal components and protein folding processes were 
mostly involved (figure 43, panel C).
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Figure 43. Biological processes associated with differently expressed proteins in unexposed and 10 days 
TCDD-exposed differentiating osteoblasts from a) univariate analysis; b) multivariate analysis. Panel c) 
refers to biological processes associated with differentially expressed proteins related to the progress of 
unexposed osteoblast differentiation. Histograms of the negative log of each p-value for the experimental 
groups (p <0.05) are shown..
4.6.2: Biological Network analysis
Further functional interpretation of the differentially expressed proteins was carried out 
by building and analyzing biological networks.
Using the shortest path algorithm to map the shortest paths of interaction among the 
differently expressed proteins, 16 out of the 18 submitted proteins highlighted by 10 




Two prominent regulatory proteins in the network were c-Fos and c-Myc. These 
interact directly with respectively three (RAB11A, lamin A, and vimentin) and four 
(lamin A, HSPA8, tropomyosin 2, and gamma actin) of the differently expressed 
proteins. Other transcription factors such as p53 and c-Jun were also identified in the 
networks, suggesting a common role in driving TCDD's effects in osteogenesis.
The relevance of these transcription factors was further highlighted when proteomic 
data derived from the multivariate analysis were analyzed. In this case 12 out of the 
18 identified proteins were clustered together in the interaction network (figure 45). 
Generation of sub-networks centered on transcription factors revealed that c-Myc and 
c-Fos were directly associated with the transcription regulation of 6 proteins (VCP, 
calreticulin, tropomyosin 2, a-enolase, lamin A, and vimentin) (figure 46, upper 
network).
Interestingly, c-Myc and p53 had a prominent role in the regulation of 11 proteins 
(tropomyosin 2, AC0N=AC02, EEF1G, a-enolase, lamin A calreticulin, ARF1, VIM, 
HSP27=HSPB1, ERP29) whose expression gradually changed as osteoblasts 
differentiated (figure 46, lower network).
4.6.3. Pathway analysis: remarks
The biological processes enrichment analysis indicate that TCDD affects mainly 
osteoblasts cell architecture and trafficking proteins, essentially related to cell motility, 
organization and survival.
The integration of the experimental results with pathway analysis identified 
transcriptional factors such as c-Fos and c-Myc as prominent factors that might 
participate in the transcriptional regulation of some of the proteins whose abundances 
were changed by TCDD.
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Additionally, the role of c-Myc and p53 as regulating factors in the proteome profile 
changes during osteoblasts differentiation provides clues to the complex interplay 
between TCDD's action and the molecules driving osteoblasts differentiation.
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Figure 44. Biological network analysis of differently expressed proteins in differentiating osteoblasts in 
response to 10 days of TCDD exposure (univariate analysis). Nodes represent proteins. Coloured circles 
represent a single protein or a group of proteins identified in our analysis. The 26S proteosome (20S core) 
node includes PSMA6 and PSMB4; the TCP1 node represents CCT1, CCT2, and CCT3. PUR9 refers to ATIC, 
HSC70 refers to HSPA8. See Appendix 7.2 for full protein names. Lines connecting the nodes indicate 
interactions of activation or induction or modification or direct binding. The direct connections relevant for 
the identified proteins are traced in blue. The shortest path network was edited by hiding some nodes and 
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Figure 45. Biological network analysis of differently expressed proteins in differentiating osteoblasts in 
response to 10 days of TCDD exposure (multivariate analysis). Nodes represent proteins. Coloured circles 
represent a single protein or a group of proteins identified in our analysis. PUR9 refers to A71C, the TCP1 
node represents CCT3, GRP78 refers to HSPA, and HSP27 refers to HSPB1. See Appendix 7.2 for full 
protein names. Lines connecting the nodes indicate interactions of activation or induction or modification 








Figure 46. Transcription regulation networks. Nodes represent proteins. Coloured circles represent a 
single protein or a group of proteins identified in our analysis. Lines connecting the nodes indicate 
interactions of activation or induction or direct binding. Upper network, interactions between the 
transcriptional factors c-Fos and c-Myc and the subset of proteins whose abundance changed in 
differentiating osteoblasts after 10 days of TCDD exposure. Lower network, interactions between the 
transcriptional factors c-Myc and p53 and the subset of proteins whose abundance changed during the 
progress of osteoblast differentiation. ACON refers to AC02, NDPK B refers to NME2, and HSP27 refers to 







Dioxins are ubiquitous environmental contaminants and immunotoxicants that are 
persistent, lipophilic, and accumulate in the food chain. While a broad range of dioxin 
toxicities have been documented, their effects on bone are still poorly understood.
Only a few experimental studies have demonstrated that bone development and 
homeostasis are targets for 2,3,7,8-tetrachlorodibenzo-yP-dioxin (TCDD), which is the 
most potent model compound for dioxins. TCDD was reported to interfere with bone 
growth modelling and mechanical strength in vivo, at doses relevant for environmental 
health risk assessment. Data from in vitro studies showed that TCDD suppresses 
differentiation of normal diploid rat osteoblasts.
Despite these earlier studies, the detailed mechanisms of TCDD-induced effects on 
bone are still unknown.
Using a proteomic approach, this study investigated the disturbances of bone 
development caused by TCDD, focusing on osteoblastogenesis. I chose the 
differentiation of rat mesenchymal stem cells to osteoblasts as a model system to 
compare protein expression in untreated and TCDD-exposed cells over three time 
points (3, 7, and 10 days of culture, covering the main phases of osteogenesis) at two 
dioxin dose levels. The two doses (InM and lOOnM) were in the range of those used in 
the literature for in vitro cell systems, sufficiently low to avoid any block in cell 
proliferation, but high enough to induce the AHR-dependent mechanism [123].
I set out to determine whether TCDD affected protein abundance and how these 
effects correlated with alterations in biochemical indices of osteoblast activity and 
differentiation, to gain further insight into the molecular mechanisms involved in 
TCCD's effect on osteoblast differentiation.
My results indicate that differentiating osteoblasts are sensitive to TCDD as measured 
by mRNA expression of differentiation markers such as Runx2 (a transcription factor
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essential for osteoblast differentiation), alkaline phosphatase (Alp, a cell-surface 
glycoprotein whose expression is acquired during matrix maturation) and osteocalcin 
(Ocn, a matrix protein synthesized by osteoblasts and used as a biomarker for bone 
formation).
The gene expression analysis indicated no change in markers expression at earlier time 
points of TCDD exposure, when cells are still proliferating (3 days) or when they enter 
the differentiation stage (7 days). After 10 days, at which point the cells should be fully 
differentiated osteoblasts, expression of all measured markers was significantly 
decreased, with the strongest inhibitory effect on the expression of osteocalcin.
These results clearly indicate time-dependent TCDD-induced changes in osteoblast 
marker expression, suggesting that TCDD inhibits osteoblast differentiation in vitro and 
supporting the anti-osteogenic potential of dioxin.
TCDD is known to mediate its effects mainly via AHR, by binding to the dioxin response 
element (DRE) located upstream of the target genes. Immunofluorescent staining 
indicated that the cells used in this study actually expressed AHR from the beginning of 
the exposure period, and that upon TCDD exposure AHR was translocated to the 
nucleus (experiments performed at the University of Oulu, Prof. Juha Tukkanen; data 
not shown). However, Alp and Ocn genes both lack DREs in their regulatory 
sequences. Therefore, the effect of TCDD on the expression of these genes is probably 
not a direct effect, but rather a secondary response mediated by AHR.
This prompted me to apply a proteome approach to my model system, in order to 
explore changes in the cellular expression of proteins that may be important signatures 
of TCCD-associated signalling events influencing osteoblast differentiation.
I have shown that at early time points of TCDD exposure (3 and 7 days) TCDD had no 
relevant effect on the >700 polypeptides that could be routinely analysed. The only 
exception was the significant decreased expression of calregulin occurring after 7 days
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of TCDD treatment. Calregulin is a chaperonin protein that regulates Ca2+ levels by 
modulation of the endoplasmatic reticulum (ER) Ca2+ storage and transport [178]. 
Thus, the reduction of calregulin might represent an early marker of the TCDD-induced 
calcium homeostasis disruption, since calregulin is also down regulated following 10 
days of exposure, at which time I showed calcium deposition was decreased in TCDD- 
exposed osteoblasts.
The most significant rearrangement of the proteome during osteoblast differentiation 
was observed following the longer time of TCDD exposure (10 days), at which time 
mRNA changes in differentiation markers were also observed. Eighteen individual 
proteins were changed in abundance mainly at the highest dose of TCDD, indicating 
dose- and time-dependent changes in protein expression.
This differential proteomic analysis was performed using a univariate statistical 
approach, which is currently the conceptually simplest and the most commonly used in 
gel differential expression analysis.
A distinctive aspect of my work was the additional use of an alternative statistical 
approach to the same dataset. In this case I applied principal component analysis 
(PCA) as an exploratory data analysis method able to visualize differences between 
complex proteome profiles.
The PCA identified particularly robust changes in the proteome profile correlated to a 
time based effect (culture days) rather than an exposure effect (TCDD doses). Despite 
this relevant time-effect, the PCA showed that the overall proteome profile was 
statistically distinguishable between untreated and treated cells only when cells were 
exposed to the highest dose of TCDD for 10 days. This finding was in accordance with 
the conclusion from the univariate approach applied to the same dataset. Furthermore 
both statistical approaches shared a fair number of proteins that are highly likely to be 
significant in the biological process investigated.
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At 10 days of exposure, TCDD strongly induced the expression of cytoskeletal 
components such as tropomyosin, vimentin and gamma actin. All these proteins are 
implicated in one or more steps of cytoskeleton protection, stress fiber assembly and 
cell motility [163, 179].
This evidence prompted me to further explore the effects of TCDD on cell architecture 
by confocal microscopy. Staining for the focal adhesion marker paxillin showed an 
increase in focal adhesion contacts in osteoblasts after TCDD treatment. This implies 
enhanced adhesion of exposed osteoblasts, which might interfere with/or reduce the 
differentiation processes [193]. Such effects on adhesion-mediated events agree with 
previous reports of alterations of cell plasticity and cell mobility after AHR activation 
[46, 193, 195].
Since cell differentiation depends on appropriate attachment to adjacent cells and/or 
extracellular matrix [196], it appears plausible that TCDD's negative effect on 
osteoblast differentiation might be related to dioxin interfering with signalling pathways 
regulating cell-cell and cell-substrate adhesion and, by extension, with the 
transmembrane signals important for cell organization and motility.
Cell adhesion and spreading are calcium-regulated, involving a plethora of calcium- 
binding proteins. One such protein is calregulin. As already mentioned, this 
multifunctional protein participates in calcium homeostasis through its calcium storage 
capacity, in protein "quality control" through its chaperonin activity and in cell adhesion 
through pathways that are still not clear [182]. It has been reported that fibroblasts 
under-expressing calregulin have a poorly adhesive phenotype [197]. However, in the 
present study TCDD-exposed osteoblasts showed a decrease in the abundance of 
calregulin, with concomitant enhanced adhesiveness. This suggests that TCDD-induced 
changes in osteoblast adhesion properties cannot be simply correlated with the 
differential expression of calregulin, but are probably integrated in additional signalling 
pathways that control cell adhesion.
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Interestingly, after 10 days of exposure, TCDD down-regulated another calcium- 
binding protein, annexin A2, which functions as a Ca2+ channel in the plasma 
membrane and in the matrix vesicles, which initiate mineralization in bone [183]. 
Under-expression of annexin A2 might therefore interfere with calcium deposition, and 
indeed it was significantly decreased after 10 days of exposure to TCDD in my cell 
system.
Further important pathways influenced by 10 days TCDD treatment are related to 
protein quality control and trafficking. These are both vital for osteoblasts and 
polarized cells, where high levels of synthesis of secreted proteins require a highly 
evolved mechanism to fold, process and secrete proteins properly. Evidence is 
emerging that tight control and coordination of the endoplasmic reticulum stress 
response is indispensable to ensure proper function and survival of professional 
secretory cells like osteoblasts [198].
In osteoblasts exposed to TCDD for 10 days there was a significant decrease in the 
expression of chaperonins containing T-complex polypeptides 1, 2 and 3 which assist in 
the folding of actin and tubulin, suggesting deregulation of the protein-folding regimen 
with consequences in cytoskeleton organization.
The intracellular trafficking machinery of osteoblasts is also likely to be impaired by the 
down-regulation of RAB11A, a member of the large superfamily of small Ras-related 
GTP-binding Rab proteins, acting as master signal components that regulate many 
aspects of vesicular transport along recycling, endocytic and exocytic pathways. Since 
the maintenance of polarity is largely dependent on endocytic sorting [199, 200], 
impaired protein trafficking control is likely to have dramatic effects on osteoblast 
secretory activity.
In this scenario, the ITCDD-strengthened expression of PSMC2, a 26S subunit 
regulatory unit, and of PSMB4, the 20S catalytic/enzymatic core, together with the 
down-regulation of PSMA6, the alpha-type subunit of the 20S proteasome, although
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apparently contradictory, might be simply a sign of changes in the proteasome subunit 
composition and activity after exposure to TCDD.
It might be therefore speculated that TCDD disrupts protein folding efficiency and 
trafficking control, impairing the functionality of osteoblasts.
The TCDD-induced up-regulation of the chaperonin HSPA8 can be viewed as an 
adaptive response of the cell to reinforce the protein-folding control process and to 
boost tolerance to stressful conditions.
I found that 10-days of TCDD treatment enhanced the abundance of valosin-containing 
protein, a general chaperone that targets many substrates to the proteasome for 
degradation [201]. Valosin-containing protein is implicated in a large number of 
biological functions and it may exert an anti-apoptotic effect [201, 202]. This is 
consistent with the lower Bax/Bcl-2 expression ratio I found in TCDD-exposed 
osteoblasts by Western blot analysis. This suggests that TCDD might reduce the 
apoptotic ability of differentiating osteoblasts. Apoptosis increases with osteoblast 
maturation in vitro and is a prominent feature during the development of the mature 
osteoblast phenotype, removing populations of cells that would otherwise inhibit 
differentiation [203]. Therefore apoptotic inactivation by TCDD may have detrimental 
effects on the efficiency of osteoblast differentiation.
The attenuation of the osteoblast differentiation process might also be associated with 
the strong down-regulation of lamin-A and all its isoforms I observed in the proteome 
profile of TCDD-exposed osteoblasts. Lamin-A, a major structural component of the 
nuclear envelope, is considered critical for cell differentiation probably by "locking" cells 
in a specific phenotypic stability [187]. Its decreased expression might therefore 
interfere with the maintenance of the osteoblasts differentiated state. It has been 




Interestingly, long-term (10 days) TCDD exposure induced changes in the expression 
of these proteins that were opposite to the expression trend observed when cells were 
grown in osteogenic conditions without dioxin.
The up-regulation of calregulin observed during the process of osteoblast 
differentiation is consistent with the reported increase in calregulin expression 
accompanying the differentiation of mouse bone marrow osteoprogenitor cells into 
preosteoblast cells upon parathyroid hormone treatment [185]. It may thus participate 
in an intracellular Ca2+ transport pathway and could act as a Ca2+ carrier to the 
mineralization front. Such role would be jeopardized by TCDD, which might impair the 
osteoblast mineralization process reducing the level of calregulin.
I found that TCDD also abolished the expression trends of annexin A2, lamin-A, 
RAB11A and chaperonins CCT1, CCT2, CCT3. These proteins showed a gradual up- 
regulation during differentiation, in accordance with their functional role in growth and 
differentiation.
The drop of their expression levels caused by TCDD is likely to impair the osteogenic 
progression and osteoblast function by lowering their secretory capacity, ability to 
maintain the differentiated state, protein folding efficiency and trafficking control.
During osteogenic differentiation, MSCs change from their characteristic fibroblast-like 
phenotype to a near spherical shape that characterizes the differentiated state, with a 
consequent change in assembly and disassembly kinetics of microfilaments dynamics 
[188].
In my model system, osteoblast differentiation was accompanied by a gradual 
decrease in the expression of tropomyosin, a major microfilament stabilizing 
component, consistent with the tropomyosin reduction reported in differentiating 
systems of non-muscle cells [189, 190]. In parallel I observed a differential expression 
of type III intermediate filament vimentin, which was reduced after 10 days of culture,
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when the majority of cells have changed their shape to a more rounded differentiated 
stage [185, 190].
Such expected changes in cytoskeletal organization during the osteogenic 
differentiation were again abolished by 10 days of TCDD exposure, which caused 
enhanced expression of all tropomyosin isoforms and vimentin.
Taken together these results indicate that, within 10 days of exposure, TCDD induces 
concerted changes in expression in the differentiating osteoblasts proteome that are in 
the opposite direction of the trend characterizing osteoblast differentiation. The 
observation that this effect occurs following 10 days of culture might indicate that later 
stages of differentiation, essential for both the development and maintenance of bone, 
might be particularly susceptible to TCDD.
Some of the proteome alterations observed after TCDD exposure in differentiating 
osteoblasts may represent specific novel targets of TCDD on cells, since it has been 
recently reported that, in rat hepatoma cells, TCDD affects the expression of 
cytoskeletal-associated proteins such as vimentin, gamma actin, tropomyosins, ANXA2, 
lamin-A, molecular chaperonin HSPA8, T-complex protein subunits CCT1-3 and protein 
degradation proteins [205]. They may therefore provide novel starting-points for 
exploring specific aspects of dioxin toxicity in mammalian cells.
The integration of my proteomics results with pathway analysis identified 
transcriptional factors such as c-fos and c-myc as prominent nodes. These factors 
might participate in the transcriptional regulation of some of the osteoblast proteins 
whose abundances were changed by TCDD. HSPA8, tropomyosin 2 and gamma actin 
can be genomic targets of the c-myc protein [206]. In addition, the expression of 
RAB11A and vimentin depend on c-fos [207, 208], while lamin-A might interact with c- 
fos and disturb bone development and homeostasis through as yet unknown 
mechanisms [209], Previous studies have demonstrated a critical role for c-fos in
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osteoblast responses to hormones and in bone matrix formation, suggesting that 
down-regulation of c-fos expression might be translated into a decrease in osteoblast 
differentiation capability [210]. Furthermore c-fos is important in gene transcription of 
osteogenic markers, such as Ocn and Alp [211], that were down-regulated by TCDD in 
this study. Finally, the reported ability of TCDD to interfere with both c-myc and c-fos 
DNA-binding activity and expression is of relevance [212, 213].
Further investigations are warranted to assess the involvement of these early-response 
genes. Their modulation is likely to play a major role in early molecular events 
surrounding TCDD-induced inhibition of osteoblast differentiation. This suggests that 
TCDD might produce effects on the osteoblast proteome through alteration of signal 
transduction mechanisms rather than by changing the abundance of key structural 
proteins.
The dioxin-responsive protein targets found in this study might be the downstream 
effect of the interactions between stress-activated pathways involved in dioxin's action 
and bone cell signalling pathways.
In conclusion, the results of this work indicate that TCDD effects the differentiation of 
osteoblasts by altering their cell architecture, adhesive properties and calcium 
homeostasis, causing an abnormal trafficking and targeting of proteins and thereby 
interfering with signals important for cell motility, organization and survival.
Additionally, integrating my experimental results with pathway analysis, I provide clues 
to the complex interplay between TCDD's action and the regulatory molecules that 
alter signal-transduction pathways regulating osteoblast differentiation.
From these observations, it is clear that the proteomics approach I used to explore the 
effect of TCDD on osteobast differentiation is a hypothesis-generating engine'rather 
than an hypothesis-testing platform. It delivers compelling hypotheses that help in
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explaining the molecular mechanisms by which endocrine-disrupting chemicals, such as 
dioxins, interfere with bone development, quality and diseases.
I am aware that focused follow-up studies that test my emerging hypotheses directly 
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7.1. List of abbreviations
AR activity rate
EF emission factor (average emission rate of a given pollutant for a given source, 
relative to the intensity of a specific activity)
I-TEQ international toxic equivalent 
MSW municipal solid waste
Protein abbreviations
ACTG1: gamma-actin;




BAX: apoptosis regulator BAX;
BCL2: apoptosis regulator Bcl-2;
CALR: calregulin;
CCTl: T-complex protein subunit alpha;
CCT2: T-complex protein 1 subunit beta;
CCT3: T-complex protein 1 subunit gamma;
GAPDH: glyceraldehyde-3-phosphate dehydrogenase;
HSPA8: heat shock cognate protein 71 kD;
LMNA: lamin-A;
Ocn: osteocalcin;
PSMA6: 20S proteasome subunit alpha type 6;
PSMB4: 20S proteasome subunit beta type 4;
PSMC2: 26S protease regulatory subunit 7;
198
Appendix
RAB11A: ras related protein Rab-llA;
RAN: GTP-binding nuclear protein Ran;
Runx2: runt-related transcription factor 2;
TCDD: 2,3,7,8-Tetrachlorodibenzo-p-dioxin;
TPM1: tropomyosin-1 alpha chain;
TPM2: tropomyosin beta chain;
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